<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clozapine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clozapine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Clozapine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12336" href="/d/html/12336.html" rel="external">see "Clozapine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12995" href="/d/html/12995.html" rel="external">see "Clozapine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708679"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Severe neutropenia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine treatment has caused severe neutropenia, defined as an absolute neutrophil count (ANC) less than 500/mm<sup>3</sup>. Severe neutropenia can lead to serious infection and death. Prior to initiating treatment, a baseline ANC must be at least 1,500/mm<sup>3</sup> for the general population and must be at least 1,000/mm<sup>3</sup> for patients with documented Benign Ethnic Neutropenia. During treatment, patients must have regular ANC monitoring. Advise patients to immediately report symptoms consistent with severe neutropenia or infection (eg, fever, weakness, lethargy, sore throat).</p>
<p style="text-indent:-2em;margin-left:2em;">Because of the risk of severe neutropenia, clozapine is available only through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension, bradycardia, syncope:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Orthostatic hypotension, bradycardia, syncope, and cardiac arrest have occurred with treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with dosages as low as 12.5 mg/day, or when restarting patients who have had even a brief interruption in treatment. Initiate treatment at 12.5 mg once or twice daily, titrate slowly, and use divided dosages to minimize risk. Use cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (eg, dehydration, use of antihypertensive medications).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Seizures:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Seizures have occurred with treatment. The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. Use caution when administering to patients with a history of seizures or other predisposing risk factors for seizure (CNS pathology, medications that lower the seizure threshold, alcohol abuse). Caution patients about engaging in any activity where sudden loss of consciousness could cause serious risk to themselves or others.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myocarditis, cardiomyopathy and mitral valve incompetence:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Fatal myocarditis and cardiomyopathy have occurred with treatment. Discontinue clozapine and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with clozapine-related myocarditis or cardiomyopathy should not be rechallenged with clozapine. Consider the possibility of myocarditis or cardiomyopathy if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or electrocardiogram (ECG) changes occur.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Clozapine is not approved for use in patients with dementia-related psychosis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F153952"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Clozaril;</li>
<li>Versacloz</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866413"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AA-Clozapine;</li>
<li>Clozaril;</li>
<li>GEN-Clozapine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F153995"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Second Generation (Atypical) Antipsychotic</li></ul></div>
<div class="block doa drugH1Div" id="F153957"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prior to initiating treatment, obtain a baseline ANC; the ANC must be ≥1,500/mm<sup>3</sup> for the general population and ≥1,000/mm<sup>3</sup> for patients with documented benign ethnic neutropenia in order to initiate treatment. To continue treatment, the ANC must be monitored regularly. Laboratory hematology results may be presented in different units; 1 mcL equals 1 mm<sup>3</sup>. Due to risks for GI hypomotility, consider concomitant use of preventative treatments (high-fiber diet, exercise, fluids, laxatives) for constipation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29230675','lexi-content-ref-27532076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29230675','lexi-content-ref-27532076'])">Ref</a></span>). The manufacturer recommends twice-daily dosing to minimize the risk of adverse effects, and in some efficacy studies, total daily dosage was administered in 3 divided doses; however, once the dose is stabilized, once-daily dosing may be tolerated in some patients and is generally given at bedtime to avoid daytime sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27182769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27182769'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b86ae9af-0983-405b-8c0b-a20590d54c4c">Agitation/Aggression and psychosis associated with dementia, severe or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation/Aggression and psychosis associated with dementia, severe or refractory (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For short-term use while addressing underlying causes of severe symptoms. Patients with dementia with Lewy bodies are at increased risk for severe adverse reactions; caution is required even with low doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 6.5 to 12.5 mg at bedtime; increase by 12.5 mg every 3 to 5 days as needed based on response and tolerability (given as divided doses in the morning and at bedtime); mean doses of 60 mg/day have been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17712102','lexi-content-ref-29401113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17712102','lexi-content-ref-29401113'])">Ref</a></span>). In patients without a clinically significant response after 4 weeks, taper and withdraw therapy. In patients with an adequate response, attempt to taper and withdraw therapy within 4 months, unless symptoms recurred with a previous taper attempt. Assess symptoms at least monthly during taper and for at least 4 months after withdrawal of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27133416'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a83c4bc1-7dd1-4c76-b8ef-e3d6cc3133fb">Bipolar disorder, treatment resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder, treatment resistant (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute mania (monotherapy or adjunctive therapy):</b>
<b>Oral:</b> Initial: 25 mg daily; increase daily dose based on response and tolerability in 25 mg increments at intervals ≥1 day to a maximum dose of 550 mg/day in 1 to 3 divided doses. Usual daily dose ~100 to 300 mg/day in 1 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616','lexi-content-ref-10831480','lexi-content-ref-25346322','lexi-content-ref-19347775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616','lexi-content-ref-10831480','lexi-content-ref-25346322','lexi-content-ref-19347775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance treatment (monotherapy or adjunctive therapy): </b>Continue dose and combination regimen that was used to achieve control of the acute episode (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616','lexi-content-ref-19347775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616','lexi-content-ref-19347775'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80d7a391-587d-4c94-81dc-51417f4dba54">Psychosis in Parkinson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psychosis in Parkinson disease (off-label use): Oral:</b> Initial: 6.25 mg/day, in 1 or 2 divided doses; increase daily dose based on response and tolerability in 6.25 or 12.5 mg increments at intervals of 3 to 7 days to a maximum dose of 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15319699','lexi-content-ref-10072410','lexi-content-ref-15090561']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15319699','lexi-content-ref-10072410','lexi-content-ref-15090561'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c642acd-fa55-4d9d-a66b-f25756b729c3">Schizophrenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia:</b>
<b>Oral:</b> Initial: 12.5 mg once or twice daily; increase daily dose, as tolerated, in increments of 25 to 50 mg at intervals ≥1 day to a target dose of 300 to 450 mg/day in 1 to 3 divided doses by the end of 2 weeks; may further titrate in increments not exceeding 100 mg and no more frequently than once or twice weekly. Maximum total daily dose: 900 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="23b59831-518d-4491-b50f-40198c976b83">Suicidal behavior in schizophrenia or schizoaffective disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Suicidal behavior in schizophrenia or schizoaffective disorder:</b>
<b>Oral:</b> Initial: 12.5 mg once or twice daily; increase daily dose, as tolerated, in increments of 25 to 50 mg daily to a target dose of 300 to 450 mg/day in 1 to 3 divided doses by the end of 2 weeks; may further titrate in increments not exceeding 100 mg and no more frequently than once or twice weekly. Mean dose is ~300 mg daily; maximum total daily dose: 900 mg.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Reinitiation of therapy:</i></b> If dosing is interrupted for ≥48 hours, therapy must be reinitiated at 12.5 mg once or twice daily to minimize the risk of hypotension, bradycardia, and syncope; if dose is well tolerated, may be increased more rapidly than with initial titration, unless cardiopulmonary arrest occurred during initial titration, then retitrate with extreme caution.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy:</i></b> In the treatment of chronic psychiatric disease, switching therapy rather than discontinuation is generally advised if side effects are intolerable or treatment is not effective. If patient insists on stopping treatment, in general, gradual dose reduction (ie, over several weeks to months) is advised to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects; the manufacturer recommends reducing the clozapine dose gradually over a period of 1 to 2 weeks if termination of therapy is not related to neutropenia. Monitor closely to allow for detection of prodromal symptoms of disease recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516','lexi-content-ref-17650054','lexi-content-ref-32670542','lexi-content-ref-Post.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Switching antipsychotics:</i></b> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include: cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). In patients with schizophrenia at high risk of relapse, the current medication may be maintained at full dose as the new medication is increased (ie, overlap); once the new medication is at therapeutic dose, the first medication is gradually decreased and discontinued over 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658','lexi-content-ref-28044008'])">Ref</a></span>). Based upon clinical experience, some experts generally prefer cross-titration and overlap approaches rather than abrupt change (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stroup.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stroup.1'])">Ref</a></span>).</p></div>
<div class="block dora drugH1Div" id="F50991293"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, labeling suggests that dose reductions may be necessary with significant impairment but does not provide specific dosing recommendations. Alternatively, an initial dose of 12.5 mg once daily has been recommended for patients with mild to moderate impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HLS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HLS.2'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988610"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, labeling suggests that dose reductions may be necessary with significant impairment.</p></div>
<div class="block doe drugH1Div" id="F153958"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;">Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. May be appropriate for labeled indications including schizophrenia, bipolar disorder, or Parkinson disease psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Prior to initiating treatment, obtain a baseline ANC; the ANC must be ≥1,500/mm<sup>3</sup> for the general population and ≥1,000/mm<sup>3</sup> for patients with documented Benign Ethnic Neutropenia (BEN) in order to initiate treatment. To continue treatment, the ANC must be monitored regularly. Laboratory hematology results may be presented in different units; 1 mcL equals 1 mm<sup>3</sup>. Due to risks for GI hypomotility, consider concomitant use of preventative treatments (high-fiber diet, exercise, fluids, laxatives) for constipation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29230675','lexi-content-ref-27532076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29230675','lexi-content-ref-27532076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Schizophrenia:</b>
<b>Oral:</b> Experience in the elderly is limited; may initiate with 12.5 mg once daily for 3 days, then increase to 25 mg once daily for 3 days as tolerated; may further increase, as tolerated, in increments of 12.5 to 25 mg daily every 3 days to desired response, up to 700 mg/day in 1 to 3 divided doses (mean dose: 300 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10074877','lexi-content-ref-25166892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10074877','lexi-content-ref-25166892'])">Ref</a></span>). Dosages in the lower range of recommended adult dosing are generally sufficient for patient with late-onset schizophrenia or psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10671383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10671383'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F52812494"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12995" href="/d/html/12995.html" rel="external">see "Clozapine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Obtain a baseline CBC, including the ANC. In order to initiate treatment, minimum baseline ANC values must be met; for the general population, the ANC must be ≥1,500/mm<sup>3</sup> and for patients with documented benign ethnic neutropenia, the ANC must be ≥1,000/mm<sup>3</sup>. Laboratory hematology results may be presented in different units; 1 mcL = 1 mm<sup>3</sup>. The ANC must be monitored regularly with continued treatment. Due to risks for GI hypomotility, consider concomitant use of preventative treatments (eg, high fiber diet, exercise, fluids, laxatives) for constipation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29230675','lexi-content-ref-27532076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29230675','lexi-content-ref-27532076'])">Ref</a></span>). Titration to the lowest effective dose should be used to minimize potential adverse effects (see "Adverse Reactions [Significant]: Considerations") including seizures (clozapine may decrease seizure threshold) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16182674','lexi-content-ref-17314729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16182674','lexi-content-ref-17314729'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6aa3ce4-ec55-424b-88b4-6ca5ef11bb97">Schizophrenia; treatment resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia; treatment resistant:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Childhood onset schizophrenia (COS) (ie, diagnosed before 13 years of age) is very rare and often misdiagnosed, thus limiting sample sizes for study (eg, approximately 30% to 50% of patients with affective or other atypical psychotic symptoms are misdiagnosed as COS, and over 90% of the initial referrals to the NIMH study of COS received alternate diagnoses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24012072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24012072'])">Ref</a></span>)). Meta-analysis and systematic review showed clozapine is safe, effective, and superior to other antipsychotics in treatment of childhood and adolescent onset schizophrenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099269']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099269'])">Ref</a></span>). Dose should be individualized based on tolerability, concomitant antipsychotic therapy, and clinical response.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years: Oral: 6.25 or 12.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Oral: 12.5 mg once or twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Titration and maintenance dosing:</i> Increase daily dose by ≤25 mg increments (lower initial doses should use smaller increments [1 to 2 times the starting dose]), as tolerated, every 3 to 5 days, to a target dose of 200 to 400 mg/day in divided doses. Dose may be divided, with a higher dose at bedtime; if excessive daytime sedation, entire dose may be at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17314729','lexi-content-ref-24129841','lexi-content-ref-8956674','lexi-content-ref-17651705','lexi-content-ref-24119631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17314729','lexi-content-ref-24129841','lexi-content-ref-8956674','lexi-content-ref-17651705','lexi-content-ref-24119631'])">Ref</a></span>). Mean effective dose range in most pediatric studies: 220 to 431 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24119631']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24119631'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Reinitiation of therapy: </i>Based on experience in adult patients, if dosing is interrupted for ≥48 hours, therapy must be reinitiated at initial doses to minimize the risk of hypotension, bradycardia, and syncope; if dose is well tolerated, may be increased more rapidly than with initial titration, unless cardiopulmonary arrest occurred during initial titration, then retitrate with extreme caution.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Children and Adolescents: In adults, the manufacturer recommends reducing the dose gradually over a period of 1 to 2 weeks if termination of therapy is not related to neutropenia. The American Academy of Child and Adolescent Psychiatry (AACAP), American Psychiatric Association (APA), Canadian Psychiatric Association (CPA), National Institute for Health and Care Excellence (NICE), and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines recommend gradually tapering antipsychotics to avoid withdrawal symptoms and minimize the risk of relapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17195735','lexi-content-ref-15000267','lexi-content-ref-23821039','lexi-content-ref-16529334','lexi-content-ref-26065063','lexi-content-ref-22834451'])">Ref</a></span>); risk for withdrawal symptoms may be highest with highly anticholinergic or dopaminergic antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When stopping antipsychotic therapy in patients with schizophrenia, the CPA guidelines recommend a gradual taper over 6 to 24 months and the APA guidelines recommend reducing the dose by 10% each month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-16529334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-16529334'])">Ref</a></span>). Continuing antiparkinsonism agents for a brief period after discontinuation may prevent withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039'])">Ref</a></span>). When switching antipsychotics, three strategies have been suggested: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic), overlap and taper (maintaining the dose of the first antipsychotic while gradually increasing the new antipsychotic, then tapering the first antipsychotic), and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Evidence supporting ideal switch strategies and taper rates is limited and results are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23821039','lexi-content-ref-15949658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23821039','lexi-content-ref-15949658'])">Ref</a></span>).</p></div>
<div class="block dorp drugH1Div" id="F52729670"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, labeling suggests that dose reductions may be necessary with significant impairment but does not provide specific dosing recommendations.</p></div>
<div class="block dohp drugH1Div" id="F52729671"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling; however, labeling suggests that dose reductions may be necessary with significant impairment.</p></div>
<div class="block arsc drugH1Div" id="F55978359"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic activity of clozapine at usual therapeutic doses is considered to be high, relative to other second-generation antipsychotics and may lead to nonadherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16928430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16928430'])">Ref</a></span>). Peripheral anticholinergic effects include <b>blurred vision</b>, <b>xerostomia,</b> urinary retention, <b>tachycardia, </b>and <b>constipation </b>(potentially resulting in severe and potentially fatal complications such as<b> intestinal obstruction </b>and ileus). Central anticholinergic effects may result in <b>cognitive dysfunction</b>, including <b>confusion</b>, new-onset <b>delirium, </b>and an increased risk of falling, particularly in older adults. However, there are conflicting data on the cognitive effects of clozapine with some studies showing a beneficial effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-29983780','lexi-content-ref-7961582','lexi-content-ref-10335669','lexi-content-ref-20631560','lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-29983780','lexi-content-ref-7961582','lexi-content-ref-10335669','lexi-content-ref-20631560','lexi-content-ref-31342625'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; believed to be mediated primarily through antagonism at muscarinic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-16928430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-16928430'])">Ref</a></span>). In addition, some anticholinergic effects are also potentiated by other pathways, such as clozapine's antiadrenergic effects contributing to urinary retention potential and clozapine’s antagonism of serotonin receptors in GI smooth muscle contributing to constipation potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-8968299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-8968299'])">Ref</a></span>). Cognitive effects may also be further mediated by clozapine-induced D2 blockade and by differences in plasma concentration ratios of clozapine and its major metabolite, N-desmethylclozapine (NDMC), with some evidence suggesting that NDMC may be associated with cognitive improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29796248','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29796248','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Variable and dependent upon:</p>
<p style="text-indent:-2em;margin-left:8em;">• Total cumulative anticholinergic burden (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline cognitive function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Interindividual variability of the pharmacokinetic and pharmacodynamic parameters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31342625']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31342625'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dyslipidemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine is strongly associated with dyslipidemia, which is a component of the metabolic syndrome observed with this pharmacologic class. Dyslipidemia observed with clozapine primarily manifests as <b>hypercholesterolemia</b> and/or <b>hypertriglyceridemia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17346932','lexi-content-ref-11603884','lexi-content-ref-16187768','lexi-content-ref-17012695','lexi-content-ref-26218604','lexi-content-ref-33410989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17346932','lexi-content-ref-11603884','lexi-content-ref-16187768','lexi-content-ref-17012695','lexi-content-ref-26218604','lexi-content-ref-33410989'])">Ref</a></span>). A 10-year naturalistic study of clozapine-treated adult patients suggested an increased risk of mortality from cardiovascular disease (CVD) secondary to disorders such as obesity, diabetes, hypertension, and hyperlipidemia; however, patients with schizophrenia have a higher risk of CVD than the general population due to lifestyle habits (eg, smoking, physical inactivity, unhealthy diet), regardless of medication use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16187768','lexi-content-ref-29670504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16187768','lexi-content-ref-29670504'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; metabolic alterations from antipsychotics can develop in as short as 3 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14747245','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14747245','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of hyperlipidemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11603884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11603884'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication use) is associated with a higher rate of morbidity/mortality compared to the general population primarily due to CVD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151456'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (potential risk factor). <b>Note:</b> Conflicting data exist on a correlation between clozapine levels and triglycerides or cholesterol; however, higher clozapine levels have been associated with an increased risk for metabolic syndrome in general (clozapine levels 1.5 times higher in patients with metabolic syndrome compared to those without) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33410989','lexi-content-ref-27681143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33410989','lexi-content-ref-27681143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risk of dyslipidemia and overall metabolic disturbances appears to be high with clozapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extrapyramidal symptoms</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine may cause extrapyramidal symptoms (EPS), also known as drug-induced movement disorders, but EPS is typically rare or uncommon in adults treated with therapeutic doses of clozapine compared to first-generation (conventional) antipsychotics, and in some studies, has been equal to or less than the control group. Incidence may be higher in children and adolescents, particularly with akathisia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33552171','lexi-content-ref-17885577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33552171','lexi-content-ref-17885577'])">Ref</a></span>); however, some limited evidence is conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11772153','lexi-content-ref-9330014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11772153','lexi-content-ref-9330014'])">Ref</a></span>). Antipsychotics can cause four main extrapyramidal reactions: Acute<b> dystonia</b>, drug-induced parkinsonism, <b>akathisia</b>, and <b>tardive dyskinesia</b>. Of these, clozapine is very rarely associated with acute dystonia or dyskinesia (acute or tardive) and some clinicians use a switch to clozapine to mitigate tardive dyskinesia induced by other antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7961551','lexi-content-ref-8866742','lexi-content-ref-29092658','lexi-content-ref-15000267','lexi-content-ref-19995222','lexi-content-ref-31347436']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7961551','lexi-content-ref-8866742','lexi-content-ref-29092658','lexi-content-ref-15000267','lexi-content-ref-19995222','lexi-content-ref-31347436'])">Ref</a></span>). EPS presenting as <b>dysphagia</b>, esophageal dysmotility, or <b>pulmonary</b>
<b>aspiration</b> have also been reported with antipsychotics which may not be recognized as EPS. Clozapine has been the sole antipsychotic in several of these case reports, although it is unknown the role and to what degree clozapine-induced EPS, -sialorrhea, and/or -anticholinergic properties may have contributed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955499','lexi-content-ref-15138897','lexi-content-ref-7962688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955499','lexi-content-ref-15138897','lexi-content-ref-7962688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> EPS: Dose-related; due to antagonism of dopaminergic D<sub>2</sub> receptors in nigrostriatal pathways; however, compared to other antipsychotics, clozapine has a much lower affinity for D<sub>2</sub> receptors and displays rapid dissociation from D<sub>2</sub> receptors (‘fast off’ phenomenon), which may contribute to the lower propensity of clozapine for EPS development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-8866742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-8866742'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Acute dystonia</span>: Rapid; in the majority of cases, dystonia usually occurs within the first 5 days after initiating antipsychotic therapy (even with the first dose, particularly in patients receiving parenteral antipsychotics) or a dosage increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Drug-induced parkinsonism</span>: Varied; onset may be delayed from days to weeks, with 50% to 75% of cases occurring within 1 month and 90% within 3 months of antipsychotic initiation, a dosage increase, or a change in the medication regimen (such as adding another antipsychotic agent or discontinuing an anticholinergic medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Akathisia</span>: Varied; may begin within several days after antipsychotic initiation but usually increases with treatment duration, occurring within 1 month in up to 50% of cases, and within 3 months in 90% of cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Tardive dyskinesia</span>: Delayed; symptoms usually appear after 1 to 2 years of continuous exposure to a dopamine 2 receptor antagonist and almost never before 3 months, with an insidious onset, evolving into a full syndrome over days and weeks, followed by symptom stabilization, and then a chronic waxing and waning of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23858394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23858394'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<span style="text-decoration: underline">Esophageal dysfunction (associated with extrapyramidal symptoms)</span>: Varied; ranges from weeks to months following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14565800']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14565800'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">EPS (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Prior history of EPS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506','lexi-content-ref-15000267','lexi-content-ref-28721057'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Younger age (in general, children and adolescents are usually at higher risk for EPS compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19861668','lexi-content-ref-33552171','lexi-content-ref-17885577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19861668','lexi-content-ref-33552171','lexi-content-ref-17885577'])">Ref</a></span>); however, some limited evidence for clozapine is conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11772153','lexi-content-ref-9330014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11772153','lexi-content-ref-9330014'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Specific antipsychotic: Clozapine has a very low propensity to cause EPS in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15000267','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15000267','lexi-content-ref-20187598'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Acute dystonia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10473482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10473482'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced parkinsonism:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22523509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22523509'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22523509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22523509'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Akathisia:</p>
<p style="text-indent:-2em;margin-left:8em;">• Higher antipsychotic dosages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29924506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29924506'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Mood disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Tardive dyskinesia: <b>Note:</b> It is unlikely that clozapine causes tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172575'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Cognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant treatment with anticholinergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diagnosis of schizophrenia or affective disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31325958']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31325958'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Greater total antipsychotic exposure (especially first-generation antipsychotics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17390261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17390261'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of extrapyramidal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32867516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32867516'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance misuse or dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29439776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29439776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Race (White or African descent). <b>Note:</b> Although early literature supported race as a potential risk factor for tardive dyskinesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8102845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8102845'])">Ref</a></span>), newer studies have challenged this assertion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28146614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28146614'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Esophageal dysfunction:</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29095482','lexi-content-ref-15138897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29095482','lexi-content-ref-15138897'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fever</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Drug-induced <b>fever </b>is common with clozapine following initiation. It is usually benign, transient, and self-limiting (lasting an average of 2.5 days and resolving by day 16 even if therapy is continued). However, fever warrants further investigation to rule out other nonbenign potential causes (eg, neuroleptic malignant syndrome [NMS], severe neutropenia, infection, myocarditis, clozapine-induced hypothermia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26166236','lexi-content-ref-32517724','lexi-content-ref-28106314','lexi-content-ref-19126823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26166236','lexi-content-ref-32517724','lexi-content-ref-28106314','lexi-content-ref-19126823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; various underlying mechanisms have been proposed (eg, infection, mild form of NMS, allergic reaction), but recent evidence suggests that clozapine-induced fever is due to a generalized inflammatory response to the immunomodulating effects of clozapine on the cytokine system, particularly due to increased levels of interleukin-6 and C-reactive protein (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28106314','lexi-content-ref-18835660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28106314','lexi-content-ref-18835660'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; usually occurs in the first 3 to 4 weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26166236','lexi-content-ref-32517724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26166236','lexi-content-ref-32517724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Titration-related (potential risk factor with dose increases &gt;50 mg/week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32517724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32517724'])">Ref</a></span>). <b>Note:</b> Fever does not seem to be dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19126823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19126823'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Gastrointestinal hypomotility</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine-induced <b>decreased gastrointestinal motility</b> is common and may result in delayed gastric emptying, GI dysmotility (small bowel or colon), and <b>constipation</b> (the cardinal feature), but it may also progress to severe and potentially life-threatening events, including <b>fecal impaction, non-Hirschsprung megacolon, paralytic ileus, intestinal obstruction, gastrointestinal infarction</b> (including ischemia), <b>gastrointestinal necrosis, </b>and <b>gastrointestinal </b>
<b>perforation</b>. Mortality related to serious GI hypomotility events is high and may be as high as 12-fold that of agranulocytosis. Preventative measures are recommended for constipation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31910056','lexi-content-ref-29230675','lexi-content-ref-29796248','lexi-content-ref-30456745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31910056','lexi-content-ref-29230675','lexi-content-ref-29796248','lexi-content-ref-30456745'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not been fully elucidated but has been mainly attributed to clozapine’s anticholinergic and antiserotonergic effects. Clozapine antagonizes cholinergic M1 and M3 receptors which can interfere with autonomic regulation of the intestine, inhibitor smooth muscle contraction, and slow intestinal transit. Antagonism of serotonin 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, 5-HT<sub>6</sub>, and 5-HT<sub>7</sub> receptors also play a role in GI motor and sensory functions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29796248','lexi-content-ref-30456745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29796248','lexi-content-ref-30456745'])">Ref</a></span>). Antiadrenergic effects may also play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31910056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31910056'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31910056','lexi-content-ref-32474068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31910056','lexi-content-ref-32474068'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of anticholinergics and other medications that decrease GI peristalsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29230675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29230675'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher daily doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31910056']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31910056'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Increased serum hepatic transaminases are common with use, including elevations 2 to 3 times greater than normal. Increased liver enzymes are usually transient and asymptomatic, with the majority not requiring discontinuation or a dose reduction unless elevations are persistent and/or accompanied by symptoms. However, there have been rare case reports of severe <b>hepatotoxicity</b> including <b>hepatitis</b>, <b>acute </b>
<b>hepatotoxicity</b>, and fulminant <b>hepatic failure</b> (including fatal cases) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19440569','lexi-content-ref-21165382','lexi-content-ref-11270919','lexi-content-ref-9241012','lexi-content-ref-25553232','lexi-content-ref-25210451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19440569','lexi-content-ref-21165382','lexi-content-ref-11270919','lexi-content-ref-9241012','lexi-content-ref-25553232','lexi-content-ref-25210451'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unknown; although, clozapine is extensively metabolized by the liver, partially via the cytochrome P450 pathway, including CYP1A2 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19440569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19440569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; increased transaminases usually occur within first several weeks following initiation and most resolve after 6 to 12 weeks; in the case reports describing serious hepatic events, onset is typically within a few days to several weeks (ie, 4 to 6 weeks) following initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19440569','lexi-content-ref-25553232','lexi-content-ref-8078987','lexi-content-ref-25210451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19440569','lexi-content-ref-25553232','lexi-content-ref-8078987','lexi-content-ref-25210451'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine is strongly associated with <b>hyperglycemia</b>, which is a component of the metabolic syndrome observed with this pharmacologic class. Glycemic abnormalities range from mild insulin resistance to new-onset<b> diabetes mellitus, exacerbation of diabetes mellitus, hyperosmolar coma</b>, and <b>diabetic ketoacidosis </b>(DKA), including fatal cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29796248','lexi-content-ref-23278567','lexi-content-ref-11603884','lexi-content-ref-16187768','lexi-content-ref-11747852','lexi-content-ref-31179433','lexi-content-ref-9328511','lexi-content-ref-26218604','lexi-content-ref-18348593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29796248','lexi-content-ref-23278567','lexi-content-ref-11603884','lexi-content-ref-16187768','lexi-content-ref-11747852','lexi-content-ref-31179433','lexi-content-ref-9328511','lexi-content-ref-26218604','lexi-content-ref-18348593'])">Ref</a></span>). A 10-year naturalistic study of clozapine-treated adult patients suggested an increased risk of mortality from cardiovascular disease (CVD) secondary to disorders such as obesity, diabetes, hypertension, and hyperlipidemia; however, patients with schizophrenia have a higher risk of CVD than the general population due to lifestyle habits (eg, smoking, physical inactivity, unhealthy diet), regardless of medication use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16187768','lexi-content-ref-29670504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16187768','lexi-content-ref-29670504'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>The mechanism is not entirely understood and is likely multifactorial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-23278567']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-23278567'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; new-onset diabetes has been observed within the first 3 months to a median onset of 3.9 years of antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28099349','lexi-content-ref-18348593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28099349','lexi-content-ref-18348593'])">Ref</a></span>). In a review of clozapine-associated diabetes reports, most cases of hyperglycemia appeared within 6 months of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11747852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11747852'])">Ref</a></span>). Clozapine-related DKA typically occurs early in the treatment course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29796248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29796248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• African American race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11747852','lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11747852','lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &lt;35 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with preexisting obesity, poor exercise habits, or other risk factors for diabetes, including family history of diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Exposures to other agents that also increase the risk of hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25497507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25497507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Treatment duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16187768','lexi-content-ref-11747852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16187768','lexi-content-ref-11747852'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Risk of metabolic disturbances appears to be high with clozapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Mortality in older patients</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Older adults with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548409','lexi-content-ref-24416588','lexi-content-ref-25786075'])">Ref</a></span>). For clozapine, several large epidemiological cohort studies in mostly schizophrenia patients have found an association between clozapine and <i>lower</i> all-cause mortality; however, these studies were not exclusive to older adults and the median or mean age at the start of the study ranging from 36 to 49 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30478891','lexi-content-ref-25154620','lexi-content-ref-31922669','lexi-content-ref-19595447','lexi-content-ref-29697804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30478891','lexi-content-ref-25154620','lexi-content-ref-31922669','lexi-content-ref-19595447','lexi-content-ref-29697804'])">Ref</a></span>). In a retrospective analysis of older adults &gt;60 years of age (mean age: 70 years) with treatment-resistant schizophrenia treated with clozapine, mortality was found to be similar with clozapine compared to other first- and second-generation antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25166892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25166892'])">Ref</a></span>). In addition, an increased incidence of cerebrovascular effects (eg, cerebrovascular accident, transient ischemic attacks), including fatalities, have been reported in some second-generation antipsychotic placebo-controlled trials, such as risperidone and olanzapine, in older adults with dementia-related psychosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24158020','lexi-content-ref-16166184','lexi-content-ref-27133416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24158020','lexi-content-ref-16166184','lexi-content-ref-27133416'])">Ref</a></span>). Of note, clozapine is not approved for the treatment of dementia-related psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Unknown; possible mechanisms include arrhythmia, cardiac arrest, and extrapyramidal effects that may increase the risk of falls, aspiration, and pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24016844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24016844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher antipsychotic dosage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25140533','lexi-content-ref-22193526','lexi-content-ref-25786075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dementia-related psychosis (eg, Lewy body dementia, Parkinson disease dementia)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myocarditis/cardiomyopathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine-induced <b>myocarditis</b>, a rare/infrequent but potentially fatal adverse event, typically occurs early in the course of therapy (ie, first 1 to 2 months) with ensuing clozapine-induced <b>cardiomyopathy</b> typically presenting later during therapy. Clinical signs and symptoms are highly variable and range from asymptomatic to nonspecific signs such as fever, chest pain, hypotension, flu-like symptoms, eosinophilia, elevated C-reactive protein, increased troponin, ECG changes, signs of heart failure, palpitations, dyspnea, and/or <b>sinus tachycardia</b>. Clozapine-induced myocarditis is associated with high mortality if not recognized early; prompt therapy discontinuation is required to prevent disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29579587','lexi-content-ref-29345690','lexi-content-ref-32494516','lexi-content-ref-32109805','lexi-content-ref-15643098','lexi-content-ref-31351758','lexi-content-ref-20361910','lexi-content-ref-12897222']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29579587','lexi-content-ref-29345690','lexi-content-ref-32494516','lexi-content-ref-32109805','lexi-content-ref-15643098','lexi-content-ref-31351758','lexi-content-ref-20361910','lexi-content-ref-12897222'])">Ref</a></span>). Cases of sudden cardiac death subsequently identified on autopsy as myocarditis with eosinophilic infiltrates have also been reported in patients newly initiated on clozapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10584719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10584719'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unclear; however, several hypotheses have been proposed for clozapine-induced cardiotoxicity, including a type 1 acute hypersensitivity reaction mediated by Ig-E, a pro-inflammatory cytokine pathway involving TNF-alpha, and a hypercatecholaminergic state contributing to increased production of free radicals and subsequent oxidative stress (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29579587','lexi-content-ref-10584719','lexi-content-ref-31351758','lexi-content-ref-29670504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29579587','lexi-content-ref-10584719','lexi-content-ref-31351758','lexi-content-ref-29670504'])">Ref</a></span>). A role of viral infections has also been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32698608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32698608'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; myocarditis usually occurs within the first 8 weeks of therapy and cardiomyopathy usually presents months or years after therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29345690','lexi-content-ref-23010488','lexi-content-ref-31957459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29345690','lexi-content-ref-23010488','lexi-content-ref-31957459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid titration and higher doses early in clozapine titration (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29579587','lexi-content-ref-23010488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29579587','lexi-content-ref-23010488'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant sodium valproate (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010488'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients living in Australia or New Zealand (potential risk factor). <b>Note:</b> Although event rates are higher in Australia and New Zealand, it is unknown if this is due to observation bias or unidentified genetic and/or environmental factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29345690','lexi-content-ref-31957459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29345690','lexi-content-ref-31957459'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuroleptic malignant syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">All antipsychotics have been associated with <b>neuroleptic malignant syndrome</b> (NMS), although the incidence is less with second-generation (atypical) antipsychotics compared to first-generation (typical) antipsychotics. There are case reports of NMS with clozapine, including monotherapy. Furthermore, clozapine-associated NMS may present with atypical features, such as absent or less intense rigidity, fever, and/or fewer extrapyramidal symptoms in general (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-18052897','lexi-content-ref-16804375','lexi-content-ref-12766935','lexi-content-ref-8830069','lexi-content-ref-18628446','lexi-content-ref-23744413','lexi-content-ref-22626633','lexi-content-ref-25324614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30375086','lexi-content-ref-25578944','lexi-content-ref-18052897','lexi-content-ref-16804375','lexi-content-ref-12766935','lexi-content-ref-8830069','lexi-content-ref-18628446','lexi-content-ref-23744413','lexi-content-ref-22626633','lexi-content-ref-25324614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; idiosyncratic. Believed to be due to a reduction in CNS dopaminergic tone, along with the dysregulation of autonomic nervous system activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25578944']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25578944'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in general, most patients develop NMS within 2 weeks of initiating an antipsychotic, and in some patients, prodromal symptoms emerge within hours of initiation; once the syndrome starts, the full syndrome usually develops in 3 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18052897','lexi-content-ref-17414689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18052897','lexi-content-ref-17414689'])">Ref</a></span>). However, there are many cases of NMS occurring months or even years after stable antipsychotic therapy, including clozapine treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18052897','lexi-content-ref-12766935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18052897','lexi-content-ref-12766935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Males are twice as likely to develop NMS compared to females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9735957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9735957'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18052897','lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18052897','lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• High-dose antipsychotic treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant lithium or a benzodiazepine (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Catatonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Disorganized speech or behavior (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Polypharmacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pharmacokinetic interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22854034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22854034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• IM administration of an antipsychotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dosage escalation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychomotor agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19213967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19213967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine commonly causes significant <b>orthostatic hypotension </b>and accompanying reflex tachycardia,<b> bradycardia, </b>and<b> dizziness </b>in adults, particularly with rapid titration. Older adults are especially vulnerable to orthostatic hypotension, and coupled with clozapine’s sedative properties, these effects increase the risk for subsequent falling. Once the dose is stabilized, giving the full dose or the majority of the full daily dose at bedtime may help reduce risk of orthostatic hypotension. If therapy is interrupted even for a brief interval (≥2 days), therapy should be retitrated to reduce the risk of orthostatic hypotension. Of note, tachycardia, not limited to reflex tachycardia, is also common with clozapine therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-20187598'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; orthostatic hypotension is attributed to alpha-1 adrenergic receptor antagonism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Rapid; per the manufacturer's labeling, risk of orthostatic hypotension is highest during the initial dose titration but can also occur following reinitiation of therapy after periods of interrupted therapy and/or subsequent dose increases.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Known cardiovascular diseases (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities) or cerebrovascular disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Known predisposing conditions (eg, hypovolemia/dehydration)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant medications that also cause or exacerbate orthostatic hypotension (eg, tricyclic antidepressants, antihypertensive medications)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (due to reduced autonomic function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid dose titration (slow titration is recommended) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (ie, temporarily lowering the dose may help manage orthostatic hypotension) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QTc prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine has been associated with dose-dependent <b>prolonged QT interval on ECG. </b>In general, clozapine’s effect on QTc prolongation is typically benign in patients without additional risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11199953','lexi-content-ref-15503744','lexi-content-ref-10901343','lexi-content-ref-23051123','lexi-content-ref-16096514','lexi-content-ref-22114630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11199953','lexi-content-ref-15503744','lexi-content-ref-10901343','lexi-content-ref-23051123','lexi-content-ref-16096514','lexi-content-ref-22114630'])">Ref</a></span>). The risk for <b>torsades de pointes</b> (TdP) is considered to be possible, but evidence supporting causality is lacking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25168784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25168784'])">Ref</a></span>). In a review of reports of QTc prolongation and/or TdP associated with clozapine at therapeutic doses, the vast majority of QTc prolongation cases (and both the TdP cases) were confounded by concomitant risk factors (eg, comedications known to prolong the QTc interval, comorbidities). Similarly, many reports of sudden death associated with clozapine therapy occurred in a setting of potentially confounding factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726','lexi-content-ref-11483480','lexi-content-ref-10831019','lexi-content-ref-12503253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726','lexi-content-ref-11483480','lexi-content-ref-10831019','lexi-content-ref-12503253'])">Ref</a></span>). Of note, clozapine is also associated with other cardiac effects, such as myocarditis and cardiomyopathy, which may also play a role in risk for QTc prolongation and/or sudden death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12897222','lexi-content-ref-22114630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12897222','lexi-content-ref-22114630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent; clozapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current (Ikr); however, clozapine also interacts with multiple receptors including dopamine, adrenergic, serotonin, muscarinic, and histamine, which may balance or mitigate its effect on the HERG K+ channel. Clozapine also affects heart rate which may influence QTc determination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29796248','lexi-content-ref-10901343','lexi-content-ref-23051123','lexi-content-ref-12503253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29796248','lexi-content-ref-10901343','lexi-content-ref-23051123','lexi-content-ref-12503253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with a reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypokalemia, hypocalcemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Co-administration of multiple medications (≥2) that prolong the QT interval or increase drug interactions that increase serum drug concentrations of QTc prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-23716032','lexi-content-ref-24803473','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Substance use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20210726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20210726'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sedation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedated state</b>
<b>(drowsiness) </b>is common with use and may cause nonadherence, impair physical and mental abilities, and may result in subsequent falling, particularly in older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-22257975','lexi-content-ref-26613638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-22257975','lexi-content-ref-26613638'])">Ref</a></span>). Most patients tolerate sedation within 6 weeks of therapy initiation; however, it may persist in many patients, particularly older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-26613638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-26613638'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Sedation is primarily attributed to H<sub>1 </sub>antagonism; clozapine is considered to have high affinity for H<sub>1</sub> receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-29796248','lexi-content-ref-28721057'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (sedation may be persistent rather than transient in this population) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (potential risk factor but not conclusive since a dose-reduction does not always mitigate effect) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-26613638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-26613638'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Clozapine is considered highly sedating (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-20187598','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-20187598','lexi-content-ref-28721057'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Seizures or myoclonus</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine is strongly associated with dose-dependent <b>seizure. </b>Clozapine also commonly causes <b>EEG pattern changes. </b>Tonic-clonic seizure is the most commonly described seizure with clozapine use followed by myoclonic seizure and atonic seizure.<b> Myoclonus </b>has also been reported in several case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26242478','lexi-content-ref-26118746','lexi-content-ref-12973403','lexi-content-ref-33866283','lexi-content-ref-23146619','lexi-content-ref-29360288','lexi-content-ref-11888352','lexi-content-ref-31738190','lexi-content-ref-23983927','lexi-content-ref-17688010','lexi-content-ref-27249081']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26242478','lexi-content-ref-26118746','lexi-content-ref-12973403','lexi-content-ref-33866283','lexi-content-ref-23146619','lexi-content-ref-29360288','lexi-content-ref-11888352','lexi-content-ref-31738190','lexi-content-ref-23983927','lexi-content-ref-17688010','lexi-content-ref-27249081'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-dependent (although exact dose-relationship is unclear); precise mechanism is unclear, although a role of inhibiting D4 (dopamine) mesolimbic and cortical receptors has been suggested. Other possible mechanisms have been suggested, such as interactions with NMDA, GABA, and glutamate receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ayaydin.1','lexi-content-ref-28449570','lexi-content-ref-9804284']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ayaydin.1','lexi-content-ref-28449570','lexi-content-ref-9804284'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Among the second-generation antipsychotics, clozapine appears to have the highest risk of seizure induction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403','lexi-content-ref-23146619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403','lexi-content-ref-23146619'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (doses &gt;600 mg/day have been historically associated with increased risk of seizure, although seizures have been reported with doses as low as 200 to 300 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28449570','lexi-content-ref-25537107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28449570','lexi-content-ref-25537107'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Antipsychotics in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• History of seizure activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of drugs that lower seizure threshold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Rapid dose titration or sudden increase in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403','lexi-content-ref-11888352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403','lexi-content-ref-11888352'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Slow drug metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Metabolic factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Drug-drug interactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12973403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12973403'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Organic brain disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20187598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20187598'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Severe neutropenia/agranulocytosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine may cause<b> severe neutropenia </b>(ANC &lt;500/mm<sup>3</sup>) in adult and pediatric patients and potentially life-threatening <b>agranulocytosis </b>(ANC &lt;100/mm<sup>3</sup>) in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8515788','lexi-content-ref-25187353','lexi-content-ref-23510445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8515788','lexi-content-ref-25187353','lexi-content-ref-23510445'])">Ref</a></span>). Due to the risk, clozapine is only available under a Risk Evaluation Mitigation Strategy (REMS), and baseline and regular ANC monitoring is required. Patients with benign ethnic neutropenia are <i>not</i> at increased risk for developing clozapine-induced severe neutropenia and may receive clozapine, but these patients require a different ANC monitoring algorithm and frequently have ANC values in the typical neutropenia range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8515788','lexi-content-ref-24338220','lexi-content-ref-30767710','lexi-content-ref-29505490','lexi-content-ref-32815018','lexi-content-ref-65644','lexi-content-ref-24419309','lexi-content-ref-28984748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8515788','lexi-content-ref-24338220','lexi-content-ref-30767710','lexi-content-ref-29505490','lexi-content-ref-32815018','lexi-content-ref-65644','lexi-content-ref-24419309','lexi-content-ref-28984748'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; idiosyncratic. Mechanism has not been fully elucidated, although an immune-mediated mechanism has been proposed. Clozapine has a high potential to undergo oxidative degradation and form nitrenium ion. The nitrenium ion may cause direct toxicity or stimulate an immune response following covalent binding to human leukocytes and forming an antigen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29796248','lexi-content-ref-32815018','lexi-content-ref-28984748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29796248','lexi-content-ref-32815018','lexi-content-ref-28984748'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; clozapine-induced agranulocytosis typically occurs in the first 18 weeks of therapy, with a few cases developing after 6 months of use. Risk is further decreased after 1 year of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32815018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32815018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of drug-induced neutropenia or preexisting low WBC or ANC</p>
<p style="text-indent:-2em;margin-left:6em;">• Age between 40 and 59 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28984748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28984748'])">Ref</a></span>). <b>Note:</b> It has also been suggested that children and adolescents are at increased risk for neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23510445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23510445'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23510445','lexi-content-ref-28984748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23510445','lexi-content-ref-28984748'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• White ethnicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28984748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28984748'])">Ref</a></span>). <b>Note:</b> It has also been suggested that Asian ethnicities may be at a higher risk for agranulocytosis, and African American and Middle Eastern ethnicities may have a higher risk for benign ethnic neutropenia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23510445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23510445'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic variants of several genes (eg, <i>HLA-DQB1 [HLA-DQB1*05:02]</i>, HLA-B alleles with a threonine at position 158 in the protein sequence [<i>HLA-B*38,39,67</i>], and <i>SLCO1B3/SLCO1B7</i>), although further studies are needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25187353','lexi-content-ref-30767710','lexi-content-ref-32815018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25187353','lexi-content-ref-30767710','lexi-content-ref-32815018'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sialorrhea</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Clozapine-induced<b> sialorrhea, </b>also known as hypersalivation or drooling, is common, may be severe, and may cause nonadherence. It can occur during the daytime but is typically much worse during sleep and may result in choking sensations during the night, nighttime awakening, hoarseness or dysphonia of the voice, and a chronic cough. Clozapine-induced sialorrhea may contribute to and increase the risk of potentially life-threatening aspiration pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10852096','lexi-content-ref-26848787','lexi-content-ref-7962689','lexi-content-ref-16514524','lexi-content-ref-20661023','lexi-content-ref-23773887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10852096','lexi-content-ref-26848787','lexi-content-ref-7962689','lexi-content-ref-16514524','lexi-content-ref-20661023','lexi-content-ref-23773887'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related (potentially); mechanism is unclear although it is believed to be due to muscarinic M<sub>4</sub> receptor agonism, alpha-2 adrenergic receptor antagonism, as well as alterations in the swallowing reflex and a decrease in laryngeal peristalsis. M1 agonism by the N-desmethylclozapine metabolite has also been postulated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-20661023','lexi-content-ref-15258717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-20661023','lexi-content-ref-15258717'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid titration (titrate slowly to reduce risk)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (potential risk factor). <b>Note:</b> Conflicting evidence exists on whether this is dose-related or not; however, a dose reduction may be considered to mitigate symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-20661023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-20661023'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Extremes of age (may be more sensitive to complications from sialorrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24338220','lexi-content-ref-16514524']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24338220','lexi-content-ref-16514524'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Temperature dysregulation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antipsychotics, including clozapine, may cause <b>disruption of body temperature regulation</b>, which may cause a potentially life-threatening <b>heatstroke </b>during predisposing conditions such as a heat wave or strenuous exercise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27074342','lexi-content-ref-15107195']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27074342','lexi-content-ref-15107195'])">Ref</a></span>). There are also a numerous case reports of potentially life-threatening <b>hypothermia </b>associated with clozapine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32517724','lexi-content-ref-19512984','lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32517724','lexi-content-ref-19512984','lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; idiosyncratic. Exact mechanism is unknown; however, body temperature is regulated by the hypothalamus with involvement of the dopamine, serotonin, and norepinephrine neurotransmitters. D<sub>2 </sub>antagonism may cause an increase in body temperature, while 5-HT<sub>2a</sub> (serotonin) receptor antagonism may cause a decrease in body temperature. Of note, clozapine has a stronger affinity for serotonin 5-HT<sub>2a</sub> receptors compared to D<sub>2 </sub>receptors where it displays a much lower affinity. Clozapine and its metabolite, N-desmethylclozapine, bind to many different receptors so it is also likely that other mechanisms are involved. In addition, antagonism of peripheral alpha-2 adrenergic receptors has also been suggested as a factor in the hypothermic effect by inhibiting peripheral responses to cooling (vasoconstriction and shivering) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32517724','lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32517724','lexi-content-ref-30398998','lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Hypothermia: Varied; antipsychotic-induced hypothermia cases indicate a typical onset in the period shortly after initiation of therapy or a dosage increase (first 7 to 10 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28936184'])">Ref</a></span>). In clozapine hypothermia case reports, the majority occurred within the first month, but some cases have developed years after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32517724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32517724'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Heat stroke:</p>
<p style="text-indent:-2em;margin-left:8em;">• Psychiatric illness (regardless of medication) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9712220','lexi-content-ref-17698676','lexi-content-ref-18941580'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Strenuous exercise, heat exposure, and dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27074342','lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27074342','lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant medication possessing anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174785','lexi-content-ref-12190212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174785','lexi-content-ref-12190212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Hypothermia:</p>
<p style="text-indent:-2em;margin-left:8em;">• In general, predisposing risk factors include: Older age, cerebrovascular accident, preexisting brain damage, hypothyroidism, malnutrition, shock, sepsis, adrenal insufficiency, diabetes, disability, burns, exfoliative dermatitis, benzodiazepine use, alcohol intoxication, kidney or liver failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555','lexi-content-ref-28936184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555','lexi-content-ref-28936184'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Schizophrenia (regardless of antipsychotic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17401555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17401555'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Venous thromboembolism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Multiple cases reports and case series of <b>deep vein thrombosis </b>(DVT) and <b>pulmonary embolism </b>(PE) (some fatal) have been associated with clozapine therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515','lexi-content-ref-10791380','lexi-content-ref-18796423','lexi-content-ref-29985823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515','lexi-content-ref-10791380','lexi-content-ref-18796423','lexi-content-ref-29985823'])">Ref</a></span>). There is also a case report of an upper-extremity deep vein thrombosis (UEDVT) in a patient with a prothrombin mutation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19127092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19127092'])">Ref</a></span>) and a case report of a cerebral venous thrombosis, a potentially life-threatening event, in a patient receiving clozapine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20473075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20473075'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Likely multifactorial; clozapine-associated sedation, obesity, and a sedentary lifestyle may increase the risk for DVT via venous stasis. Of note, independent of drug therapy, obesity is associated with inflammation and hypercoagulability and psychiatric disorders are associated with a sedentary lifestyle. In addition, clozapine's affinity for serotonin 5-HT<sub>2A </sub>receptors may affect platelet aggregation. It has also been suggested that clozapine may also have an effect on activated partial thromboplastin time, antiphospholipid antibodies, and C-reactive protein, although more research is needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18796423','lexi-content-ref-29985823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18796423','lexi-content-ref-29985823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in a systematic review of PE case reports, the authors found the highest incidence within the first 6 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29985823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29985823'])">Ref</a></span>); however, in another systemic review PE cases, the authors describe an anywhere from a few days to several years after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31528276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31528276'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">DVT/PE, in general:</p>
<p style="text-indent:-2em;margin-left:8em;">• Obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515','lexi-content-ref-18796423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515','lexi-content-ref-18796423'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic factors (eg, factor V Leiden mutation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515','lexi-content-ref-20473075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515','lexi-content-ref-20473075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Gynecologic/pelvic surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Indwelling venous catheter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Pregnancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Drugs such as oral contraceptives (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Recent immobility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Recent surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20473075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20473075'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Major trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15280515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15280515'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Clozapine is strongly associated with significant <b>weight gain </b>(increase of ≥7% from baseline) in children, adolescents, and adults, which is a component of the metabolic syndrome observed with this pharmacologic class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31524318','lexi-content-ref-21495734','lexi-content-ref-28883731','lexi-content-ref-22009159','lexi-content-ref-25590213','lexi-content-ref-17109073','lexi-content-ref-19675512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31524318','lexi-content-ref-21495734','lexi-content-ref-28883731','lexi-content-ref-22009159','lexi-content-ref-25590213','lexi-content-ref-17109073','lexi-content-ref-19675512'])">Ref</a></span>). A 10-year naturalistic study of clozapine-treated adult patients suggested an increased risk of mortality from cardiovascular disease secondary to disorders such as obesity, diabetes, hypertension, and hyperlipidemia; however, patients with schizophrenia have a higher risk of cardiovascular disease than the general population due to lifestyle habits (eg, smoking, physical inactivity, unhealthy diet), regardless of medication use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16187768','lexi-content-ref-29670504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16187768','lexi-content-ref-29670504'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Multiple proposed mechanisms, including actions at serotonin, dopamine, histamine, and muscarinic receptors, with differing effects on weight gain by the different antipsychotic agents explained by differing affinity at these receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-26218604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-26218604'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; antipsychotic-induced weight gain usually occurs rapidly in the period following initiation, then gradually decreases and flattens over several months with patients continuing to gain weight in the long term; the time before weight begins to plateau varies by antipsychotic, with a time of 42 to 46 months for clozapine before weight beings to plateau (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic polymorphisms (some evidence suggests that clozapine-induced weight gain is associated with polymorphisms in genes encoding CYP2C19, leptin, leptin receptor, and the serotonin receptor HTR2C) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26218604','lexi-content-ref-27681143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26218604','lexi-content-ref-27681143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Parental BMI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (antipsychotics in general; data are lacking to suggest there is a disproportionately higher weight gain with clozapine in this population compared to adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22009159','lexi-content-ref-17109073','lexi-content-ref-20702068','lexi-content-ref-15998156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22009159','lexi-content-ref-17109073','lexi-content-ref-20702068','lexi-content-ref-15998156'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Factors associated with rapid weight gain in the initial period: Younger age, lower BMI, more robust response to antipsychotic, and increase in appetite; rapid weight gain of &gt;5% in the first month has been observed as the best predictor for significant long-term weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (although weight gain plateaus, patients continue to gain weight over time) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Schizophrenia (regardless of medication) is associated with a higher prevalence of obesity compared to the general population due to components of the illness, such as negative symptoms, sedentary lifestyles, and unhealthy diets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861176'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Specific antipsychotic: Clozapine is considered to have a high propensity for causing weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28883731','lexi-content-ref-22009159','lexi-content-ref-28721057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28883731','lexi-content-ref-22009159','lexi-content-ref-28721057'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F153919"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (4% to 12%), hypotension (9% to 13%), tachycardia (17% to 25%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 1</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Chlorpromazine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment-resistant schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">842</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (8% to 38%)<span class="lexi-table-link-container"> (<a aria-label="Hypercholesterolemia table link" class="lexi-table-link" data-table-id="lexi-content-hypercholesterolemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypercholesterolemia')">table 2</a>)</span><span class="table-link" style="display:none;">Hypercholesterolemia</span>, hyperglycemia (27% to 42%)<span class="lexi-table-link-container"> (<a aria-label="Hyperglycemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperglycemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperglycemia')">table 3</a>)</span><span class="table-link" style="display:none;">Hyperglycemia</span>, hypertriglyceridemia, weight gain (4% to 31%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypercholesterolemia" frame="border" id="lexi-content-hypercholesterolemia" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Hypercholesterolemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">79</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">34</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Change (at least once) from baseline: Borderline (200 to 239 mg/dL) to high (≥240 mg/dL)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">222</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">132</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Change (at least once) from baseline: Normal (&lt;200 mg/dL) to high (≥240 mg/dL)</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperglycemia" frame="border" id="lexi-content-hyperglycemia" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Hyperglycemia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">42%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">57</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">43</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Change (at least once) from baseline in fasting blood glucose: Borderline (100 to 125 mg/dL) to high (≥126 mg/dL)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">198</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">135</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Change (at least once) from baseline in fasting blood glucose: Normal (&lt;100 mg/dL) to high (≥126 mg/dL)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (14% to 25%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 4</a>)</span><span class="table-link" style="display:none;">Constipation</span>, decreased gastrointestinal motility (literature suggests an incidence of 31%) (Cohen 2017), dyspepsia (14%), nausea (≤17%), sialorrhea (13% to 48%)<span class="lexi-table-link-container"> (<a aria-label="Sialorrhea table link" class="lexi-table-link" data-table-id="lexi-content-sialorrhea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sialorrhea')">table 5</a>)</span><span class="table-link" style="display:none;">Sialorrhea</span>, vomiting (≤17%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Suicidal behavior in schizophrenia or schizoaffective disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">479</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment-resistant schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">842</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sialorrhea" frame="border" id="lexi-content-sialorrhea" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Sialorrhea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">48%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Suicidal behavior in schizophrenia or schizoaffective disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">479</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment-resistant schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">31%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">842</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (14% to 27%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 6</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (≤46%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 7</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, EEG pattern changes (literature suggests an incidence of 63%) (Goyal 2011), insomnia (2% to 20%), sedated state (≤39%)<span class="lexi-table-link-container"> (<a aria-label="Sedated State table link" class="lexi-table-link" data-table-id="lexi-content-sedated-state" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sedated-state')">table 8</a>)</span><span class="table-link" style="display:none;">Sedated State</span>, vertigo (≤19%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Suicidal behavior in schizophrenia or schizoaffective disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">479</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment-resistant schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">842</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "dizziness/vertigo"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Olanzapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">46%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Suicidal behavior in schizophrenia or schizoaffective disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">479</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">477</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">842</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "drowsiness/sedation"</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sedated State" frame="border" id="lexi-content-sedated-state" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Sedated State</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment-resistant schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">842</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Defined as "drowsiness/sedation"</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Fever table link" class="lexi-table-link" data-table-id="lexi-content-fever" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fever')">table 9</a>)</span><span class="table-link" style="display:none;">Fever</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fever" frame="border" id="lexi-content-fever" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Fever</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Chlorpromazine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment-resistant schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">842</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Syncope (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (6%), skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (≤4%), diarrhea (2%), heartburn (≤4%), xerostomia (5% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia')">table 10</a>)</span><span class="table-link" style="display:none;">Xerostomia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia" frame="border" id="lexi-content-xerostomia" rules="all">
<caption style="text-align:center;">
<b>Clozapine: Adverse Reaction: Xerostomia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Chlorpromazine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Clozapine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Chlorpromazine)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment-resistant schizophrenia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">126</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">142</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">842</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine abnormality (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (literature suggests an incidence up to 1% to 2%) (Alvir 1993), eosinophilia (1%) (Chatterton 1997; Lally 2019; Majumder 2011; Monteleone 2021), leukopenia (≤3%), neutropenia (≤3%, can be severe neutropenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (4%), akathisia (3%), akinesia (≤4%), confusion (3%), fatigue (2%), headache (7% to 10%), nightmares (≤4%), restlessness (4%), seizure (3%; dose related), sleep disturbance (≤4%), tremor (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hypokinesia (≤4%), muscle rigidity (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, orthostatic hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Tardive dyskinesia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Wang 2020), atrial fibrillation (Low 1998), cardiomyopathy (Garg 2020), deep vein thrombosis (including upper extremity deep vein thrombosis) (Tripp 2011, Vayá 2008), mitral valve insufficiency, myocarditis (Datta 2018), palpitations (Kumar 2020), pericarditis (Sahyouni 2021), prolonged QT interval on ECG (Sharma 2011), pulmonary embolism (Poudyal 2019), sinus tachycardia (Gurrera 2022), supraventricular tachycardia (Kirpekar 2015), torsades de pointes, ventricular ectopy (Kumar 2020), ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatologic reaction (symmetrical drug-related intertriginous and flexural exanthema [SDRIFE]) (Suvarna 2020), dyschromia, erythema multiforme, skin photosensitivity, Stevens-Johnson syndrome (Wu 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (new onset) (Koller 2001), diabetes mellitus with hyperosmolar coma, diabetic ketoacidosis (Pierides 1997), exacerbation of diabetes mellitus (Koller 2001), heatstroke (Hoffmann 2016), hyperuricemia, hyponatremia, increased libido (Thomson 2018), pheochromocytoma (pseudo) (Li 1997), weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis (DeRemer 2019), appendicitis (Steinert 2021), cholestasis, colitis (including <i>Clostridioides difficile</i> colitis, necrotizing enterocolitis, and neutropenic enterocolitis) (Gurrera 2022; Rask 2020), dysphagia, esophagitis (Ma 2022), fecal impaction (Osterman 2017), gastrointestinal reflux disease (Gurrera 2022), gastrointestinal infarction, gastrointestinal necrosis (Osterman 2017), gastrointestinal perforation (Nakajima 2020), gastrointestinal ulcer, intestinal obstruction, mesenteric ischemia (Palmer 2008), non-Hirschsprung megacolon, paralytic ileus, peritonitis (Freudenreich 2000), sialadenitis (parotitis) (Hinze-Selch 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nocturnal enuresis (Gurrera 2022), priapism (Donizete da Costa 2015), retrograde ejaculation, urinary incontinence (Gurrera 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (Rajagopal 2005), granulocytopenia, hyperleukocytosis (Augustin 2021), increased erythrocyte sedimentation rate, increased hematocrit, increased hemoglobin, leukemia (Augustin 2021; Chrétien 2021), lymphocytopenia (Rajagopal 2005), malignant lymphoma (Chrétien 2021), thrombocytopenia (Gurrera 2022), thrombocytosis (Gurrera 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatotoxicity (Kane 2014), hepatic cirrhosis, hepatic failure (Chang 2009), hepatic fibrosis, hepatic necrosis (Chang 2009), hepatitis (including cholestatic hepatitis and fulminant hepatitis) (Gurrera 2022; Wu Chou 2014), hepatotoxicity (Wu Chou 2014), increased liver enzymes (Gurrera 2022), jaundice (Chang 2009), liver steatosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Tatar 2014), drug reaction with eosinophilia and systemic symptoms (Moazez 2018, Sander 2019), hypersensitivity angiitis (Penaskovic 2005), hypersensitivity reaction (Dimitri Valente 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (Mace 2022), sepsis (Senn 1977)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal electroencephalogram (Gurrera 2022), cataplexy, cerebral thrombosis (venous) (Srinivasaraju 2010), cognitive dysfunction (Rajji 2010), delirium (Gurrera 2022), disruption of body temperature regulation (Gurrera 2022), drug withdrawal (including catatonia) (Belteczki 2021), hypothermia (Burk 2020), myasthenia, myoclonus (Praharaj 2010b), neuroleptic malignant syndrome (Corallo 2007), obsessive compulsive disorder (symptoms) (Gurrera 2022), paresthesia, restless leg syndrome, status epilepticus, stuttering (Jaguga 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dystonia (acute) (Kaplan 2019), increased creatine phosphokinase in blood specimen, rhabdomyolysis (Koren 1998), systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Angle-closure glaucoma, periorbital edema (Teodoro 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Au 2004), renal failure syndrome (Davis 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Lower respiratory tract infection, pleural effusion (Kane 2014), pneumonia (Mace 2022), pneumonitis (Torrico 2020), pulmonary aspiration (Saenger 2016), sleep apnea (including obstructive sleep apnea syndrome [Shirani 2011])</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Polyserositis (Catalano 1997)</p></div>
<div class="block coi drugH1Div" id="F153935"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity to clozapine or any component of the formulation (eg, photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson syndrome [SJS])</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Myeloproliferative disorders; history of toxic or idiosyncratic agranulocytosis or severe granulocytopenia (unless due to previous chemotherapy); concomitant use with other agents that suppress bone marrow function; active hepatic disease associated with nausea, anorexia, or jaundice; progressive hepatic disease or hepatic failure; paralytic ileus; uncontrolled epilepsy; severe CNS depression or comatose states; severe renal impairment; severe cardiac disease (eg, myocarditis); patients unable to undergo blood testing</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F153916"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute infectious/inflammatory processes: Elevation of serum clozapine levels have been reported in the setting of acute infection or inflammatory process. Reactions ranging from mild sedation to symptoms requiring an ICU level of care have been reported. Significant increases of serum levels do not always correlate with clinical signs and symptoms of clozapine toxicity. Signs and symptoms such as hypotension, sialorrhea, and sedation that cannot be explained by other medications or conditions may necessitate a temporary dose reduction or discontinuation, depending on the severity (Clark 2017; Leung 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• GI motility: Use with caution in patients with decreased GI motility as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic disease or impairment; monitor hepatic function regularly. Dosage reduction may be necessary in patients with significant hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic conditions: Use with caution in patients with certain ophthalmic conditions (eg, visual problems) as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dosage reduction may be necessary in patients with significant renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary retention (eg, benign prostatic hyperplasia): Use with caution in patients with urinary retention as anticholinergic effects may exacerbate underlying condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2D6 poor metabolizers: Clozapine concentrations may be increased in CYP2D6 poor metabolizers. Dose reduction may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: The older adult patients are more susceptible to adverse effects. Older adult patients may be at increased risk of seizures due to an increased prevalence of predisposing factors (Gareri 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Smokers: Clozapine levels may be lower in patients who smoke. Smokers may require twice the daily dose as nonsmokers in order to obtain an equivalent clozapine concentration (Tsuda 2014). Smoking cessation may cause toxicity in a patient stabilized on clozapine. Monitor change in smoking patterns. Consider baseline serum clozapine levels and/or empiric dosage adjustments (30% to 40% reduction) in patients expected to have a prolonged hospital stay with forced smoking cessation. Case reports suggest symptoms from increasing clozapine concentrations may develop 2 to 4 weeks after smoking cessation (Lowe 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Brand/generic: Use caution when converting from brand to generic formulation; poor tolerability, including relapse, has been reported usually soon after product switch (1 to 3 months); monitor closely during this time (Bobo 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: FazaClo oral disintegrating tablets contain phenylalanine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: In general, when discontinuing antipsychotic therapy, gradually taper antipsychotics to avoid physical withdrawal symptoms and rebound symptoms (APA [Keepers 2020]; WFSBP [Hasan 2012]); the manufacturer recommends reducing the clozapine dose gradually over a period of 1 to 2 weeks if termination of therapy is not related to neutropenia. Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Lambert 2007; Moncrieff 2020). The risk of withdrawal symptoms is highest following abrupt discontinuation of highly anticholinergic or dopaminergic antipsychotics (Cerovecki 2013). Patients with chronic symptoms, repeated relapses, and clear diagnostic features of schizophrenia are at risk for poor outcomes if medications are discontinued (APA [Keepers 2020]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878394"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Similar to adult experience, the American Academy of Child and Adolescent Psychiatry (AACAP) guidelines recommend gradually tapering antipsychotics to avoid discontinuation symptoms and minimize the risk of relapse (AACAP [McClellan 2007]).</p></div>
<div class="block foc drugH1Div" id="F153928"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Versacloz: 50 mg/mL (100 mL) [contains methylparaben sodium, propylparaben sodium]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clozaril: 25 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clozaril: 50 mg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clozaril: 100 mg, 200 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg, 25 mg, 100 mg, 150 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F153912"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F153937"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Versacloz Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $10.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (cloZAPine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $2.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $3.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $8.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $20.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $27.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (cloZAPine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.43 - $1.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.12 - $3.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $2.46 - $6.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Clozaril Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $7.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $12.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $18.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $35.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866414"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clozaril: 25 mg, 50 mg, 100 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg, 200 mg</p></div>
<div class="block accres drugH1Div" id="F11218426"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">
<b>Canada:</b> Currently, there are multiple manufacturers that distribute clozapine and each manufacturer has its own registry and distribution system. Patients must be registered in a database that includes their location, prescribing physician, testing laboratory, and dispensing pharmacist before using clozapine. Patients may not be switched from one brand of clozapine to another without completion of a new registry-specific patient registration form by signed by the prescribing physician. Information specific to each monitoring program is available from the individual manufacturers.</p></div>
<div class="block adm drugH1Div" id="F153932"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to food. Total daily dose may be divided into uneven doses with larger dose administered at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">Orally disintegrating tablet: Remove from foil blister by peeling apart (do not push tablet through the foil). Remove immediately prior to use. Place tablet in mouth and chew or allow to dissolve; swallow with saliva. If dosing requires splitting tablet, throw unused portion away.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Shake bottle prior to use. Using syringe adaptor and oral syringe provided withdrawal dose from bottle. Administer immediately after preparation using the oral syringe provided.</p></div>
<div class="block admp drugH1Div" id="F52612446"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to food. Total daily dose may be divided into uneven doses with larger dose administered at bedtime.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Immediately prior to use, gently remove the tablet from the bottle or blister package by peeling the foil from the blister (do not push tablet through the foil). Upon removing, place tablet in mouth; it may be allowed to dissolve, chewed, or swallowed with saliva (no water is needed). If dosing requires splitting tablet, throw unused portion away.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Oral syringes, a bottle neck adaptor should be provided. Appropriate syringe size dependent upon dose: Use the 1-mL syringe for doses ≤50 mg and the 9-mL syringe for doses &gt;50 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Shake the bottle for 10 seconds, then remove the cap. For the first use of the bottle, after removing the cap, push the adaptor into the top of the bottle. Once dose is withdrawn from the bottle, it should be administered immediately and not stored for later use. After use, re-cap the bottle and rinse the syringe with water.</p></div>
<div class="block use drugH1Div" id="F153931"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Schizophrenia, treatment resistant:</b> Treatment of severely ill patients with schizophrenia who fail to respond adequately to antipsychotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Suicidal behavior in schizophrenia or schizoaffective disorder:</b> To reduce the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for reexperiencing suicidal behavior, based on history and recent clinical state.</p></div>
<div class="block off-label drugH1Div" id="F25475266"><span class="drugH1">Use: Off-Label: Adult</span><p>Agitation/aggression and psychosis associated with dementia, severe or refractory; Bipolar disorder (treatment resistant); Psychosis in Parkinson disease</p></div>
<div class="block mst drugH1Div" id="F154003"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CloZAPine may be confused with clonazePAM, cloNIDine, KlonoPIN</p>
<p style="text-indent:-2em;margin-left:4em;">Clozaril may be confused with Clinoril, Colazal</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F153989"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F153921"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: May enhance the QTc-prolonging effect of CloZAPine. Adagrasib may increase the serum concentration of CloZAPine. Management: Consider alternatives to this combination. If combined, monitor for increased clozapine toxicities, including QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adalimumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: CloZAPine may diminish the therapeutic effect of Alpha-/Beta-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the QTc-prolonging effect of CloZAPine. Amiodarone may increase the serum concentration of CloZAPine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the constipating effect of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): Antipsychotic Agents (Second Generation [Atypical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines: May enhance the adverse/toxic effect of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bimekizumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CloZAPine may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. Brexpiprazole may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabergoline: May diminish the therapeutic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May enhance the myelosuppressive effect of CloZAPine. More specifically, the risk of bone marrow suppression with this combination may be increased due to the independent myelosuppressive effects of the drugs. CarBAMazepine may decrease the serum concentration of CloZAPine. Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Consider increased monitoring for neutropenia<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May enhance the QTc-prolonging effect of CloZAPine. Ciprofloxacin (Systemic) may increase the serum concentration of CloZAPine. Management: Reduce the clozapine dose to one-third of the original dose when adding ciprofloxacin and monitor closely for evidence of excessive QTc prolongation and clozapine toxicity.  Resume the previous clozapine dose following ciprofloxacin discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: CloZAPine may enhance the QTc-prolonging effect of Citalopram. CloZAPine may enhance the serotonergic effect of Citalopram. This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, serotonin syndrome, and neuroleptic malignant syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Clarithromycin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: May enhance the adverse/toxic effect of CloZAPine. COVID-19 Vaccines may increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Weak): May decrease the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of CloZAPine. Management: Reduce the dose of clozapine to one-third of the original dose when adding a strong CYP1A2 inhibitor and monitor patient response closely. Return to the original clozapine dose when the strong CYP1A2 inhibitor is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Weak): May increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of CloZAPine. Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Clozapine dose reduction and further monitoring may be required when strong CYP3A4 inducers are discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Weak): May decrease the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: May enhance the QTc-prolonging effect of CloZAPine. Dabrafenib may decrease the serum concentration of CloZAPine. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Additionally, monitor for decreased clozapine concentrations and efficacy.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Donepezil: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of CloZAPine. Encorafenib may decrease the serum concentration of CloZAPine. Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation, ventricular arrhythmias, and decreased clozapine concentrations. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: CloZAPine may enhance the QTc-prolonging effect of Escitalopram. CloZAPine may enhance the serotonergic effect of Escitalopram. This could result in serotonin syndrome.  Management: Monitor for QTc interval prolongation, ventricular arrhythmias, serotonin syndrome, and neuroleptic malignant syndrome when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of CloZAPine. Fexinidazole may increase the serum concentration of CloZAPine. Management: Monitor for increased clozapine toxicities, including QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inducers) may decrease the serum concentration of Filgotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: May enhance the myelosuppressive effect of CloZAPine. CloZAPine may enhance the QTc-prolonging effect of Fluorouracil Products. Management: Monitor for QTc interval prolongation and ventricular arrhythmias, including torsades de pointes when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarbidopa: May decrease the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: Antipsychotic Agents may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Huperzine A: May enhance the neurotoxic (central) effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CloZAPine. Lemborexant may increase the serum concentration of CloZAPine. Management: Dosage adjustments of lemborexant and clozapine may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Consider monitoring clozapine concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Antipsychotic Agents may enhance the arrhythmogenic effect of Mequitazine.  Management: Consider alternatives to one of these agents when possible.  While this combination is not specifically contraindicated, mequitazine labeling describes this combination as discouraged.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for extrapyramidal symptoms and excessive sedation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Myelosuppressive Agents: May enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: May decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation, ventricular arrhythmias, including torsades de pointes, when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylephrine (Systemic): CloZAPine may diminish the therapeutic effect of Phenylephrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: QT-prolonging Antipsychotics (Moderate Risk) may enhance the QTc-prolonging effect of Propofol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of CloZAPine. Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the constipating effect of CloZAPine. CloZAPine may enhance the QTc-prolonging effect of QT-prolonging Antidepressants (Moderate Risk). Management: Consider alternatives to this combination whenever possible. If combined, consider prophylactic laxatives and monitor closely for signs and symptoms of gastrointestinal hypomotility, QTc prolongation, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): CloZAPine may enhance the QTc-prolonging effect of QT-prolonging Kinase Inhibitors (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Miscellaneous Agents (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CloZAPine may enhance the anticholinergic effect of QuiNIDine. CloZAPine may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of CloZAPine.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May enhance the QTc-prolonging effect of CloZAPine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Antipsychotic Agents may enhance the adverse/toxic effect of Sulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May decrease the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, the risk for NMS and extrapyramidal symptoms may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for myocarditis, neutropenia, or CNS toxicities may be increased. Valproate Products may decrease serum concentrations of the active metabolite(s) of CloZAPine. Valproate Products may increase the serum concentration of CloZAPine. Valproate Products may decrease the serum concentration of CloZAPine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing Diabetes Insipidus may diminish the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic hormone effects of vasopressin may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F153938"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Clozapine crosses the placenta and can be detected in the fetal blood and amniotic fluid (Barnas 1994; Imaz 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome information following maternal use of clozapine during pregnancy is limited (Beex-Oosterhuis 2020; Larsen 2015; Mehta 2017; Nguyen 2020). Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms) and/or withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.</p>
<p style="text-indent:0em;margin-top:2em;">The American College of Obstetricians and Gynecologists (ACOG) recommends that therapy during pregnancy be individualized; treatment with psychiatric medications during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. Safety data related to atypical antipsychotics during pregnancy is limited and routine use is not recommended. However, if a woman is inadvertently exposed to an atypical antipsychotic while pregnant, continuing therapy may be preferable to switching to an agent that the fetus has not yet been exposed to; consider risk:benefit (ACOG 2008). An increased risk of exacerbation of psychosis should be considered when discontinuing or changing treatment during pregnancy and postpartum. In general, other agents are preferred for use in pregnancy; however, clozapine may be used in women who cannot be switched to recommended antipsychotics (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers are encouraged to enroll women 18 to 45 years of age exposed to clozapine during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or http://www.womensmentalhealth.org/pregnancyregistry).</p></div>
<div class="block brc drugH1Div" id="F10912630"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Clozapine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Clozapine breast milk concentrations were higher than the maternal plasma in one case report (Barnas 1994).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother; breastfed infants should be monitored for excess sedation. Due to the potential for adverse effects to an infant exposed via breast milk, use of clozapine is not recommended in breastfeeding women (Larsen 2015).</p></div>
<div class="block dic drugH1Div" id="F153939"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F153925"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">
<b>The only mandatory monitoring is the routine ANC, however, monitoring of several other clinical outcomes is recommended. Clozapine-treated patients should be monitored as frequently as possible in the first few weeks during titration.</b></p>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;">Frequency of Antipsychotic Monitoring<sup>a,b</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Monitoring parameter</p></th>
<th align="center">
<p style="text-indent:0em;">Frequency of monitoring</p></th>
<th align="center">
<p style="text-indent:0em;">Comments</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>a </sup>For all monitoring parameters, it is appropriate to check at baseline and when clinically relevant (based on symptoms or suspected adverse reactions) in addition to the timeline.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>b </sup>ADA 2004, APA [Keepers 2020], De Hert 2011a, De Hert 2011b, Gugger 2011, Knoph 2018; Nielsen 2012, Palmer 2008, manufacturer's labeling.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>c </sup>Signs and symptoms of myocarditis include asymptomatic tachycardia, chest pain, eosinophilia, fatigue, fever, palpitations, peripheral edema, and shortness of breath.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>d </sup>Risk factors for extrapyramidal symptoms (EPS) include prior history of EPS, high doses of antipsychotics, young age (children and adolescents at higher risk than adults), and dopaminergic affinity of individual antipsychotic.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>e </sup>Risk factors for tardive dyskinesia include age &gt;55 years; females; White or African ethnicity; presence of a mood disorder, intellectual disability, or central nervous system injury; and past or current EPS.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Adherence</p></td>
<td align="center">
<p style="text-indent:0em;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Blood chemistries (electrolytes, renal function, liver function, thyroid stimulating hormone)</p></td>
<td align="center">
<p style="text-indent:0em;">Annually</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Bowel function</p></td>
<td align="center">
<p style="text-indent:0em;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">CBC (ANC)</p></td>
<td align="center">
<p style="text-indent:0em;">Refer to “ANC monitoring” section following this table (~weekly for 6 months, biweekly for 6 months, then monthly after 1 year).</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">ECG</p></td>
<td align="center">
<p style="text-indent:0em;">Check at baseline to monitor for myocarditis only if there are cardiac risk factors; repeat if significant change in dose or addition of other QTc-prolonging drugs in patients with risk factors or elevated baseline QTc.</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Echocardiogram</p></td>
<td align="center">
<p style="text-indent:0em;">Check at baseline only if there are cardiac risk factors; repeat if signs or symptoms of myocarditis develop.<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;">To monitor for myocarditis</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Extrapyramidal symptoms</p></td>
<td align="center">
<p style="text-indent:0em;">Every visit; 4 weeks after initiation and dose change; annually. Use a formalized rating scale at least annually or every 6 months if high risk.<sup>d</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Fall risk</p></td>
<td align="center">
<p style="text-indent:0em;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Fasting plasma glucose/HbA<sub>1c</sub></p></td>
<td align="center">
<p style="text-indent:0em;">12 weeks after initiation and dose change; annually.</p></td>
<td align="center">
<p style="text-indent:0em;">Check more frequently than annually if abnormal. Follow diabetes guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Lipid panel</p></td>
<td align="center">
<p style="text-indent:0em;">12 weeks after initiation and dose change; annually.</p></td>
<td align="center">
<p style="text-indent:0em;">Check more frequently than annually if abnormal. Follow lipid guidelines.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Mental status and alertness</p></td>
<td align="center">
<p style="text-indent:0em;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Metabolic syndrome history</p></td>
<td align="center">
<p style="text-indent:0em;">Annually</p></td>
<td align="center">
<p style="text-indent:0em;">Evaluate for personal and family history of obesity, diabetes, dyslipidemia, hypertension, or cardiovascular disease.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Myocarditis monitoring (C-reactive protein, eosinophils, troponin)</p></td>
<td align="center">
<p style="text-indent:0em;">Repeat weekly during first 6 weeks of treatment <b>OR</b> if signs or symptoms of myocarditis develop.<sup>c</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Prolactin</p></td>
<td align="center">
<p style="text-indent:0em;">Ask about symptoms at every visit until dose is stable. Check prolactin level if symptoms are reported.</p></td>
<td align="center">
<p style="text-indent:0em;">Hyperprolactinemia symptoms: Changes in menstruation, libido, gynecomastia, development of galactorrhea, and erectile and ejaculatory function.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Serum clozapine concentration</p></td>
<td align="center">
<p style="text-indent:0em;">As clinically appropriate.</p></td>
<td align="center">
<p style="text-indent:0em;">Check concentrations when trying to establish maintenance dose or to confirm adherence.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Smoking patterns</p></td>
<td align="center">
<p style="text-indent:0em;">Regularly; assess with hospitalization.</p></td>
<td align="center">
<p style="text-indent:0em;">Cessation may cause toxicity in a patient stabilized on clozapine. In patients expected to have a prolonged hospital stay with forced smoking cessation, consider baseline serum clozapine levels and/or empiric dosage adjustments.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Tardive dyskinesia</p></td>
<td align="center">
<p style="text-indent:0em;">Every visit; annually. Use a formalized rating scale at least annually or every 6 months if high risk.<sup>e</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Vital signs (BP, orthostatics, temperature, pulse, signs of infection)</p></td>
<td align="center">
<p style="text-indent:0em;">Every visit (at least weekly during first 3 to 4 weeks of treatment); 4 weeks after dose change. May stop monitoring temperature after first 8 weeks of treatment.</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Weight/height/BMI</p></td>
<td align="center">
<p style="text-indent:0em;">8 and 12 weeks after initiation and dose change; quarterly.</p></td>
<td align="center">
<p style="text-indent:0em;">Consider monitoring waist circumference at baseline and annually, especially in patients with or at risk for metabolic syndrome. Consider changing antipsychotic if BMI increases by ≥1 unit. Some experts recommend checking weight and height at every visit.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>ANC monitoring:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>US labeling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> See below for considerations during COVID-19 quarantine, in patients with benign ethnic neutropenia (BEN), hospice situations, use of concurrent medications that cause neutropenia, and Canadian labeling. Laboratory hematology results may be presented in different units; 1 mcL = 1 mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General population:</b> Prior to initiating treatment, obtain a baseline ANC; the ANC must be ≥1,500/mm<sup>3</sup> for the general population in order to initiate treatment. During the first 6 months of treatment, monitor the ANC weekly. If the ANC remains ≥1,500/mm<sup>3</sup>, the monitoring frequency can be reduced to every 2 weeks for the next 6 months. If the ANC remains ≥1,500/mm<sup>3</sup> for the second 6 months of continuous therapy, the ANC monitoring frequency can be reduced to once every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment interruption:</i> If ANC is ≥1,500/mm<sup>3</sup> and treatment is interrupted for &lt;30 days, continue monitoring as before; if ≥30 days, monitor as if a new patient.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment discontinuation:</i> For abrupt clozapine discontinuation for a reason unrelated to neutropenia in the general population, continuation of ANC monitoring is recommended until the ANC is ≥1,500/mm<sup>3</sup>. Additional ANC monitoring is required for any patient reporting onset of fever, defined as a temperature of ≥38.5°C (≥101.3°F), during the 2 weeks after discontinuation.</p>
<p style="text-indent:-2em;margin-left:8em;">Monitor patients for psychosis and cholinergic rebound (eg, headache, nausea, vomiting, diarrhea, profuse diaphoresis).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hematologic toxicity monitoring:</i> Confirm all initial reports of ANC &lt;1,500/mm<sup>3</sup> with a repeat ANC within 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Fever: Interrupt clozapine as a precautionary measure in any patient who develops a fever, defined as a temperature of ≥38.5°C (≥101.3°F), and obtain an ANC level. Fever is often the first sign of neutropenic infection, however, it is also a symptom of BEN.</p>
<p style="text-indent:-2em;margin-left:8em;">Mild neutropenia (1,000 to 1,499/mm<sup>3</sup>): Continue treatment; monitor ANC 3 times weekly until ≥1,500/mm<sup>3 </sup>and then return to previous monitoring schedule.</p>
<p style="text-indent:-2em;margin-left:8em;">Moderate neutropenia (500 to 999/mm<sup>3</sup>): Interrupt therapy, recommend hematology consultation, and begin daily ANC monitoring until ANC ≥1,000/mm<sup>3</sup> and then may consider restarting therapy. Follow with 3 times weekly monitoring until ANC ≥1,500/mm<sup>3</sup>. Once ANC ≥1,500/mm<sup>3</sup>, check ANC weekly for 4 weeks and then return to previous monitoring schedule.</p>
<p style="text-indent:-2em;margin-left:10em;">If fever occurs in any patient with an ANC &lt;1,000/mm<sup>3</sup>, initiate appropriate workup and treatment for infection.</p>
<p style="text-indent:-2em;margin-left:8em;">Severe neutropenia (&lt;500/mm<sup>3</sup>): Interrupt therapy, recommend hematology consultation, and begin daily ANC monitoring until ANC ≥1,000/mm<sup>3</sup>. Follow with 3 times weekly monitoring until ANC ≥1,500/mm<sup>3</sup>. Do not rechallenge unless prescriber determines benefits outweigh risks. If rechallenged, resume treatment as a new patient once ANC ≥1,500/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Benign ethnic neutropenia:</b> Prior to initiating treatment, obtain at least 2 baseline ANC levels, including the ANC; the ANC must be ≥1,000/mm<sup>3</sup> for patients with documented BEN in order to initiate treatment. During the first 6 months of treatment, monitor the ANC weekly. If the ANC remains ≥1,000/mm<sup>3</sup>, the monitoring frequency can be reduced to every 2 weeks for the next 6 months. If the ANC remains ≥1,000/mm<sup>3</sup> for the second 6 months of continuous therapy, the ANC monitoring frequency can be reduced to once every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment interruption:</i> If ANC is ≥1,000/mm<sup>3</sup> and treatment is interrupted for &lt;30 days, continue monitoring as before; if ≥30 days, monitor as if a new patient.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment discontinuation:</i> For abrupt clozapine discontinuation for a reason unrelated to neutropenia in patients with BEN, continuation of ANC monitoring is recommended until the ANC is ≥1,000/mm<sup>3</sup> or above the baseline. Additional ANC monitoring is required for any patient reporting onset of fever, defined as a temperature of ≥38.5°C (≥101.3°F), during the 2 weeks after discontinuation.</p>
<p style="text-indent:-2em;margin-left:8em;">Monitor patients for psychosis and cholinergic rebound (eg, headache, nausea, vomiting, diarrhea, profuse diaphoresis).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hematologic toxicity monitoring:</i> Confirm all initial reports of ANC &lt;1,500/mm<sup>3</sup> with a repeat ANC within 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Fever: Interrupt clozapine as a precautionary measure in any patient who develops a fever, defined as a temperature of ≥38.5°C (≥101.3°F), and obtain an ANC level. Fever is often the first sign of neutropenic infection, however, it is also a symptom of BEN.</p>
<p style="text-indent:-2em;margin-left:8em;">BEN (500 to 999/mm<sup>3</sup>): Continue therapy, recommend hematology consultation, and begin 3 times weekly ANC monitoring until ANC ≥1,000/mm<sup>3</sup> or greater than or equal to patient's known baseline. Once ANC ≥1,000/mm<sup>3</sup> or patient's known baseline, check ANC weekly for 4 weeks and then return to previous monitoring schedule.</p>
<p style="text-indent:-2em;margin-left:10em;">If fever occurs in any patient with an ANC &lt;1,000/mm<sup>3</sup>, initiate appropriate workup and treatment for infection.</p>
<p style="text-indent:-2em;margin-left:8em;">Severe BEN (&lt;500/mm<sup>3</sup>): Interrupt therapy, recommend hematology consultation, and begin daily ANC monitoring until ANC ≥500/mm<sup>3</sup>. Follow with 3 times weekly monitoring until ANC greater than or equal to patient's baseline. Do not rechallenge unless prescriber determines benefits outweigh risks. If rechallenged, resume treatment as a new patient once ANC ≥1,000/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>COVID-19 considerations:</b> Due to challenges with self-isolation or quarantine, the FDA recommends considering whether or not there are compelling reasons to complete required laboratory testing and to weigh the benefits and risks of continuing treatment in the absence of laboratory testing. The FDA does not intend to take action for failing to adhere to REMS requirements (FDA 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">A meta-analysis of 7 studies suggests the risk for neutropenia peaks within the first month of therapy and drops over time to negligible levels by 1 year of treatment (Myles 2018). Some experts suggest it may be reasonable to forego testing in patients who have received clozapine for ≥1 year and have never had an ANC &lt;2,000/mm<sup>3</sup> (or &lt;1,500/mm<sup>3</sup> if history of benign ethnic neutropenia). Patients <b>without</b> ANC monitoring who develop symptoms such as sore throat and fever should be assessed for neutropenia <b>and</b> COVID-19 (Freudenreich 2020). Expert consensus guidelines suggest the following modifications for consideration (Siskind 2020):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>ANC monitoring:</i></b></p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Continuous clozapine treatment for 1 year:</i> If there is no safe or practical access to lab draws, may reduce frequency of ANC testing to every 3 months and dispense a 90-day supply if patient has never had an ANC &lt;2,000/mm<sup>3</sup> (or &lt;1,500/mm<sup>3</sup> if history of benign ethnic neutropenia).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Continuous clozapine treatment for 6 to 12 months</i>: Make decisions about ANC monitoring on a case by case basis.</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Initiating clozapine:</i> Adhere to standard protocols for ANC monitoring for the first 6 months.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Infection symptoms: </i></b></p>
<p style="text-indent:-2em;margin-left:10em;">Patients <b>without </b>ANC monitoring who develop symptoms such as sore throat and fever should be assessed for neutropenia <b>and</b> COVID-19 (Freudenreich 2020). Considerations with COVID-19 and other infections include:</p>
<p style="text-indent:-2em;margin-left:12em;">• In patients with any symptoms of infection such as cough, fever and chills, sore throat, or other flu-like symptoms, complete an urgent physician assessment including an ANC. Clozapine may be associated with a higher risk of pneumonia due to sialorrhea and aspiration.</p>
<p style="text-indent:-2em;margin-left:12em;">• Clozapine levels may increase with acute systemic infections and lead to symptoms of acute clozapine toxicity including sedation, myoclonus, and seizures. In addition, patients with respiratory infections may reduce or cease smoking, also leading to increased clozapine levels. If patients with fever and flu-like symptoms develop symptoms of clozapine toxicity, consider reducing the clozapine dose by up to 50%. Continue the lower dose until 3 days after the fever has subsided, then increase slowly to the pre-fever dose. Use clozapine serum levels as needed to assist with dosing adjustments, particularly after large dose changes, inadequate response, or unexpected adverse effects (Siskind 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hospice patients:</b> For hospice patients (ie, terminally ill patients with an estimated life expectancy of ≤6 months), ANC monitoring may be reduced to a frequency of once every 6 months after a discussion with the patient and caregiver. Base ANC monitoring on individual treatment needs to control psychiatric symptoms and terminal illness.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Concurrent use of other drugs associated with neutropenia:</b> If clozapine is used concurrently with an agent known to cause neutropenia (eg, some chemotherapeutic agents), consider monitoring patients more closely. Consult with treating oncologist in patients receiving concomitant chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Canadian labeling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Prior to initiating treatment, obtain a baseline ANC; the ANC must be ≥2,000/mm<sup>3</sup> in order to initiate treatment. Initiate treatment in an inpatient setting or an outpatient setting with medical supervision and monitor of vital signs for at least 6 to 8 hours after the first few doses. During the first 6 months (26 weeks) of treatment, ANC should be obtained at baseline and at least weekly. If count remains acceptable (ANC ≥2,000/mm<sup>3</sup>) during this time period, then may be monitored every other week for the next 6 months (26 weeks). If ANC continues to remain within these acceptable limits after the second 6 months (26 weeks) of therapy, monitoring can be decreased to every 4 weeks.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Special populations:</i> Patients with low WBC counts because of benign ethnic neutropenia should be given special consideration and may be started on clozapine after consultation with a hematologist. Patients with a history of bone marrow disorders should be evaluated by a hematologist prior to starting clozapine; therapy may be initiated if the benefit outweighs the risk.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment interruption: </i>
<b>Note:</b> Only applies to patients with ANC ≥2,000/mm<sup>3</sup>. If treatment is interrupted for <b>&lt;3 days</b>, continue monitoring as before. If <b>≥3 days</b> of therapy interruption, resume weekly hematologic monitoring for an additional 6 weeks, then resume previous monitoring schedule. If treatment is interrupted for &gt;4 weeks, monitor as if a new patient.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic toxicity monitoring:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ANC 1,500 to 2,000/mm<sup>3</sup>: Continue treatment; monitor ANC twice weekly until counts stabilize or increase, then return to previous monitoring schedule.</p>
<p style="text-indent:-2em;margin-left:6em;">ANC &lt;1,500/mm<sup>3</sup>: Discontinue treatment and do not rechallenge patient; continue to monitor WBC/ANC daily until hematologic abnormality is resolved; monitor for signs of infection. If WBC falls &lt;1,000/mm<sup>3</sup> or ANC falls &lt;500/mm<sup>3</sup>, place patient in protective isolation with close observation.</p>
<p style="text-indent:-2em;margin-left:6em;">Eosinophilia (eosinophil count &gt;3,000/mm<sup>3</sup>): Discontinue treatment and restart only after the eosinophil count is &lt;1,000/mm<sup>3</sup>. Patients with both eosinophilia and clozapine-induced myocarditis should not be re-exposed to clozapine.</p>
<p style="text-indent:-2em;margin-left:6em;">Thrombocytopenia (platelet count &lt;50,000/mm<sup>3</sup>): Discontinue treatment.</p></div>
<div class="block rer drugH1Div" id="F22120318"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples: Draw trough ~10 hours (range: 8 to 12 hours) after last dose; typically immediately before morning dose (Gaertner 2001b; Hiemke 2018; VanderZwaag 1996).</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic reference range (clozapine only): 350 to 600 ng/mL (SI: 1,071 to 1,836 nmol/L). Ratios of clozapine to the metabolite norclozapine may provide perspectives on the metabolism of clozapine. A clozapine:norclozapine ratio &lt;2 suggests the involvement of factors that induce clozapine metabolism, including cigarette smoking and interacting medications. A ratio &gt;2 suggests a nontrough sample, a recent missed dose, or metabolism inhibition or saturation (Costa-Dookhan 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Laboratory alert level (clozapine): 1,000 ng/mL (SI: 3,060 nmol/L) (Hiemke 2018).</p></div>
<div class="block pha drugH1Div" id="F153915"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The therapeutic efficacy of clozapine (dibenzodiazepine antipsychotic) is proposed to be mediated through antagonism of the dopamine type 2 (D<sub>2</sub>) and serotonin type 2A (5-HT<sub>2A</sub>) receptors. In addition, it acts as an antagonist at alpha-adrenergic, histamine H<sub>1</sub>, cholinergic, and other dopaminergic and serotonergic receptors. </p></div>
<div class="block phk drugH1Div" id="F153934"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Bipolar disorder, acute mania: Initial effects may be observed within days of treatment with continued improvements over 1 to 2 weeks (Goikolea 2013; Tohen 2000; Welten 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">Parkinson disease psychosis: Initial effects may be observed within 1 week with continued improvements over 2 to 3 months (Pintor 2012; Pollak 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">Schizophrenia: Initial effects may be observed within 1 to 2 weeks of treatment with continued improvements through 4 to 8 weeks (Adnan 2022; Agid 2003; Levine 2010). In treatment resistant patients receiving clozapine longer trials of 8 to 12 weeks are recommended (CPA [Remington 2017]; Lee 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Variable.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 97% to serum proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP1A2 (primary), 2C19, 3A4 and 2D6; forms metabolites with limited (desmethyl metabolite) or no activity (hydroxylated and N-oxide derivative derivatives). <b>Note:</b> A pediatric pharmacokinetic study (n=6; age: 9 to 16 years) found higher concentrations of the desmethyl metabolite in comparison to clozapine (especially in females) when compared to data from adult studies; the authors suggest that both the parent drug and desmethyl metabolite contribute to the efficacy and adverse effect profile in children and adolescents (Frazier 2003; Sheehan 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 27% to 50% (not affected by food); orally disintegrating tablets, regular tablets, and oral suspension are bioequivalent (Gareri 2003; Guitton 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Steady state: 12 hours (range: 4 to 66 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Suspension: 2.2 hours (range: 1 to 3.5 hours); Tablets: 2.5 hours (range: 1 to 6 hours); Dispersible tablets: 2.3 hours (range: 1 to 6 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~50%) and feces (30%) with trace amounts of unchanged drug.</p></div>
<div class="block phksp drugH1Div" id="F51220854"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clozapine concentrations may be increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clozapine concentrations may be increased.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869369"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Clozaril | Leponex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Clozapina Fabra | Clozapina Lemax | Clozapina Rospaw | Lapenax | Sequax</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Clozapin accord | Lanolept | Leponex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Clopine | Clozapine synthon | Clozaril | Clozitor | Versacloz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Sensipin | Sizopin | Zapenia</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Clozapine accord | Excloza | Leponex | Xenopal | Xenopalan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Clozapina | Leponex | Okotico | Pinazan | Xynaz | Zolapin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Clopin eco | Clozapin mepha | Clozapin viatris | Leponex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dicomex | Leponex | Lodux</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Clofax | Clozapina | Clozapina mk | Clozaren | Dicomex | Discole | Drugtech dicomex | Labincloz | Leponex | Sicozapina | Tanyl | Zapen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alemoxan | Clozapin | Clozapin sandoz | Leponex</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Clozapin | Clozapin 1a pharma | Clozapin beta | Clozapin Biomo | Clozapin ct | Clozapin glenmark | Clozapin hexal | Clozapin neuraxpharm | Clozapin puren | Clozapin ratiopharm | Clozapin sandoz | Elcrit | Leponex</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Clozapin "2care4" | Clozapin hexal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Atipil | Clopsine | Leponex | Tibuza</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Clopsine | Clozapina | Leponex | Luverina | Zapen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Clozapine accord | Leponex</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Clozapex | Leponex | Medazepine | Schizonex | Zaclo</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Clozapina aurovitaS | Leponex | Nemea | Nemea EFG</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Clozapin hexal | Clozapine accord | Clozapine alpharma | Froidir | Leponex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clozapine accord | Clozapine arrow | Clozapine eg | Clozapine Merck | Clozapine Panpharma | Clozapine teva | Clozapine zentiva | Leponex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Clozaril | Denzapine | Zaponex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Clopine | Clozaril</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Clozapine Remedica | Leponex | Sanosen | Zaniq</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alemoxan | Clozapine Gerot | Leponex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Clopine | Clorilex | Clozaril | Leponex | Lozap | Nuzip | Sizoril</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Clozaril | Denzapine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Leponex | Lozapine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Chrozap | Cipin 100 | Clomach | Clopin | Cloza | Clozabest | Clozamat | Klopin | Kloza | Lozapin | Neuropin | Pilzep | Psyclo | Pyne | Refract | Sizopin | Skizoril | Soloquin | Syclop | Vizonic | Zaporil | Zopin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Clozapina | Clozapina accord | Clozapina aurobindo | Clozapina doc | Clozapina Orion | Clozapina Teva | Leponex</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Clozaril</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Leponex | Moclopin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Clozaril | Clzapin | Clzapine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lanolept | Leponex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Azaleptin | Clozapine accord | Leponex</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Azaleptin | Clozapin | Clozapine accord | Leponex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Clopsine | Leponex | Sicrep</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anzapine | Anzaril | Clopine | Clozarem | Clozaril</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Xycloza</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Clozapine Auro | Clozapine cf | Clozapine Glenmark | Clozapine leyden delta | Clozapine PCH | Leponex | Zaponex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Clozapin hexal | Leponex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Clopine | Clozaril | Versacloz</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clozapina | Epizol | Leponex | Refraxol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Clopixene | Ihope | Leponex | Nirva | Sizopin | Syclop | Ziproc</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amlepo | Bio zapine | Caliana | Carapine | Cepin | Cloprex | Clozamed | Clozaril | Clozcare | Ekloz | Glipin | Saveril | Welzapine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Clopizam | Klozapol | Leponex | Symcloza</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Clozaril | Fazaclo</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Clozapina | Clozapina Generis | Clozapina Mylan | Clozapina ratiopharm | Leponex | Ozapim</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clozapin quimfa | Clozapina celsius | Dicomex | Luverina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Azaleprol | Azalepticon | Azaleptin | Closastene | Clozapin | Clozapin Avexima | Clozapinum | Leponex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Clozapine accord | Clozapine actavis | Clozapine mylan | Clozapine orifarm | Clozapine sandoz | Clozapine teva | Froidir | Leponex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Clozaril</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Clozapine accord | Leponex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Clopaze | Cloril | Clozamed | Clozaril</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Leponex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Clonex | Leponex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Clopine | Closian | Clozaril | Mezapin | Uspen | Zapine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Asaleptolum | Azaleptin | Azaleptol | Azapin | Clozapin sandoz | Leponex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Leponex | Luverina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Clozapina | Leponex</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Clozapyl</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen Clozapine | Cloment | Leponex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins-Obstetrics, "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation," <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35099269">
<a name="35099269"></a>Adnan M, Motiwala F, Trivedi C, Sultana T, Mansuri Z, Jain S. Clozapine for management of childhood and adolescent-onset schizophrenia: a systematic review and meta-analysis. <i>J Child Adolesc Psychopharmacol</i>. 2022;32(1):2-11. doi:10.1089/cap.2021.0092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/35099269/pubmed" id="35099269" target="_blank">35099269</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11199953">
<a name="11199953"></a>Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. <i>J Clin Psychopharmacol</i>. 2001;21(1):8-13. doi:10.1097/00004714-200102000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11199953/pubmed" id="11199953" target="_blank">11199953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14662555">
<a name="14662555"></a>Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. <i>Arch Gen Psychiatry</i>. 2003;60(12):1228-1235. doi:10.1001/archpsyc.60.12.1228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/14662555/pubmed" id="14662555" target="_blank">14662555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12188977">
<a name="12188977"></a>Alfaro CL, Wudarsky M, Nicolson R, et al, "Correlation of Antipsychotic and Prolactin Concentrations in Children and Adolescents Acutely Treated With Haloperidol, Clozapine or Olanzapine," <i>J Child Adolesc Psychopharmacol</i>, 2002, 12(2):83-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/12188977/pubmed" id="12188977" target="_blank">12188977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31524318">
<a name="31524318"></a>Alonso-Pedrero L, Bes-Rastrollo M, Marti A. Effects of antidepressant and antipsychotic use on weight gain: a systematic review. <i>Obes Rev</i>. 2019;20(12):1680-1690. doi:10.1111/obr.12934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31524318/pubmed" id="31524318" target="_blank">31524318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20210726">
<a name="20210726"></a>Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. <i>Curr Drug Saf</i>. 2010;5(1):97-104. doi:10.2174/157488610789869265<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20210726/pubmed" id="20210726" target="_blank">20210726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8515788">
<a name="8515788"></a>Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. <i>N Engl J Med</i>. 1993;329(3):162-167. doi:10.1056/NEJM199307153290303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8515788/pubmed" id="8515788" target="_blank">8515788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14747245">
<a name="14747245"></a>American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>Diabetes Care</i>. 2004;27(2):596-601. doi:10.2337/diacare.27.2.596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/14747245/pubmed" id="14747245" target="_blank">14747245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15003083">
<a name="15003083"></a>American Diabetes Association (ADA), American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. <i>J Clin Psychiatry</i>. 2004;65(2):267-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15003083/pubmed" id="15003083" target="_blank">15003083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11958165">
<a name="11958165"></a>American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. <i>American Journal of Psychiatry.</i> 2002;159(4 Suppl):1-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11958165/pubmed" id="11958165" target="_blank">11958165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861176">
<a name="28861176"></a>Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. <i>World J Diabetes</i>. 2017;8(8):390-396. doi:10.4239/wjd.v8.i8.390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28861176/pubmed" id="28861176" target="_blank">28861176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30375086">
<a name="30375086"></a>Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. <i>Psychiatry Clin Neurosci</i>. 2019;73(1):27-33. doi:10.1111/pcn.12793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/30375086/pubmed" id="30375086" target="_blank">30375086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7640149">
<a name="7640149"></a>Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. <i>Br J Clin Pharmacol</i>. 1995;39(4):417-420.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/7640149/pubmed" id="7640149" target="_blank">7640149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15285988">
<a name="15285988"></a>Au AF, Luthra V, Stern R. Clozapine-induced acute interstitial nephritis. <i>Am J Psychiatry</i>. 2004;161(8):1501. doi:10.1176/appi.ajp.161.8.1501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15285988/pubmed" id="15285988" target="_blank">15285988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34141565">
<a name="34141565"></a>Augustin NB, Maroules M. Hyperleukocytosis during clozapine treatment: a rare presentation of B-cell Acute lymphoblastic leukemia [published correction appears in Leuk Res Rep. 2022;17:100307]. <i>Leuk Res Rep</i>. 2021;15:100253. doi:10.1016/j.lrr.2021.100253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/34141565/pubmed" id="34141565" target="_blank">34141565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ayaydin.1">
<a name="Ayaydin.1"></a>Ayaydin H, Ulgar SB. Control of seizures in a clozapine-treated schizophrenia patient, using valproate: a case report. <i>Psychiatry and Clinical Psychopharmacology</i>. 2019;29(4):529-532. doi:10.1080/24750573.2018.1468640</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9712220">
<a name="9712220"></a>Bark N. Deaths of psychiatric patients during heat waves. <i>Psychiatr Serv</i>. 1998;49(8):1088-1090. doi:10.1176/ps.49.8.1088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9712220/pubmed" id="9712220" target="_blank">9712220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8185013">
<a name="8185013"></a>Barnas C, Bergant A, Hummer M, et al, "Clozapine Concentrations in Maternal and Fetal Plasma, Amniotic Fluid, and Breast Milk," <i>Am J Psychiatry</i>, 1994, 151(6):945.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8185013/pubmed" id="8185013" target="_blank">8185013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32378285">
<a name="32378285"></a>Beex-Oosterhuis MM, Samb A, Heerdink ER, et al. Safety of clozapine use during pregnancy: Analysis of international pharmacovigilance data. <i>Pharmacoepidemiol Drug Saf</i>. 2020;29(6):725-735. doi:10.1002/pds.5016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32378285/pubmed" id="32378285" target="_blank">32378285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29579587">
<a name="29579587"></a>Bellissima BL, Tingle MD, Cicović A, Alawami M, Kenedi C. A systematic review of clozapine-induced myocarditis [published correction appears in <i>Int J Cardiol</i>. 2018 Apr 11]. <i>Int J Cardiol</i>. 2018;259:122-129. doi:10.1016/j.ijcard.2017.12.102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29579587/pubmed" id="29579587" target="_blank">29579587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34132673">
<a name="34132673"></a>Belteczki Z, Ujvari J, Dome P. Clozapine withdrawal-induced malignant catatonia or neuroleptic malignant syndrome: a case report and a brief review of the literature. <i>Clin Neuropharmacol</i>. 2021;44(4):148-153. doi:10.1097/WNF.0000000000000462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/34132673/pubmed" id="34132673" target="_blank">34132673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25578944">
<a name="25578944"></a>Belvederi Murri M, Guaglianone A, Bugliani M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. <i>Drugs R D</i>. 2015;15(1):45-62. doi:10.1007/s40268-014-0078-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25578944/pubmed" id="25578944" target="_blank">25578944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24338220">
<a name="24338220"></a>Bishara D, Taylor D. Adverse effects of clozapine in older patients: epidemiology, prevention and management. <i>Drugs Aging</i>. 2014;31(1):11-20. doi:10.1007/s40266-013-0144-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24338220/pubmed" id="24338220" target="_blank">24338220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31910056">
<a name="31910056"></a>Blackman G, Kapila A, Grosskopf CM, Dratcu L. Focussing on the fundaments - assessing and treating clozapine induced gastrointestinal hypomotility. <i>Int J Psychiatry Clin Pract</i>. 2020;24(1):18-19. doi:10.1080/13651501.2019.1710538<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31910056/pubmed" id="31910056" target="_blank">31910056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242478">
<a name="26242478"></a>Bloechliger M, Rüegg S, Jick SS, Meier CR, Bodmer M. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis. <i>CNS Drugs</i>. 2015;29(7):591-603. doi:10.1007/s40263-015-0262-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26242478/pubmed" id="26242478" target="_blank">26242478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20044366">
<a name="20044366"></a>Bobo WV, Stovall JA, Knostman M, et al. Converting From Brand-Name to Generic Clozapine: A Review of Effectiveness and Tolerability Data. <i>Am J Health Syst Pharm</i>. 2010;67(1):27-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20044366/pubmed" id="20044366" target="_blank">20044366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28449570">
<a name="28449570"></a>Bolu A, Akarsu S, Pan E, Aydemir E, Oznur T. Low-dose Clozapine-induced seizure: a case report. <i>Clin Psychopharmacol Neurosci</i>. 2017;15(2):190-193. doi:10.9758/cpn.2017.15.2.190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28449570/pubmed" id="28449570" target="_blank">28449570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698676">
<a name="17698676"></a>Bouchama A, Dehbi M, Mohamed G, Matthies F, Shoukri M, Menne B. Prognostic factors in heat wave related deaths: a meta-analysis. <i>Arch Intern Med</i>. 2007;167(20):2170-2176. doi:10.1001/archinte.167.20.ira70009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17698676/pubmed" id="17698676" target="_blank">17698676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26166236">
<a name="26166236"></a>Bruno V, Valiente-Gómez A, Alcoverro O. Clozapine and fever: a case of continued therapy with clozapine. <i>Clin Neuropharmacol</i>. 2015;38(4):151-153. doi:10.1097/WNF.0000000000000088<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26166236/pubmed" id="26166236" target="_blank">26166236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32517724">
<a name="32517724"></a>Burk BG, Ward AH, Clark B. A case report of acute hypothermia during initial inpatient clozapine titration with review of current literature on clozapine-induced temperature dysregulations. <i>BMC Psychiatry</i>. 2020;20(1):290. doi:10.1186/s12888-020-02695-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32517724/pubmed" id="32517724" target="_blank">32517724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16529334">
<a name="16529334"></a>Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. <i>Can J Psychiatry</i>. 2005;50(13)(suppl 1):7S-57S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16529334/pubmed" id="16529334" target="_blank">16529334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28146614">
<a name="28146614"></a>Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. <i>J Clin Psychiatry</i>. 2017;78(3):e264-e278. doi:10.4088/JCP.16r10832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28146614/pubmed" id="28146614" target="_blank">28146614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172575">
<a name="21172575"></a>Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. <i>Neurol Clin</i>. 2011;29(1):127-viii. doi:10.1016/j.ncl.2010.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/21172575/pubmed" id="21172575" target="_blank">21172575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151456">
<a name="15151456"></a>Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. <i>J Clin Psychiatry</i>. 2004;65 Suppl 7:4-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15151456/pubmed" id="15151456" target="_blank">15151456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9260733">
<a name="9260733"></a>Catalano G, Catalano MC, Frankel Wetter RL. Clozapine induced polyserositis. <i>Clin Neuropharmacol</i>. 1997;20(4):352-356. doi:10.1097/00002826-199708000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9260733/pubmed" id="9260733" target="_blank">9260733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23821039">
<a name="23821039"></a>Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. <i>CNS Drugs</i>. 2013;27(7):545-572. doi: 10.1007/s40263-013-0079-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23821039/pubmed" id="23821039" target="_blank">23821039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19440569">
<a name="19440569"></a>Chang A, Krygier DS, Chatur N, Yoshida EM. Clozapine-induced fatal fulminant hepatic failure: a case report. <i>Can J Gastroenterol</i>. 2009;23(5):376-378. doi:10.1155/2009/503916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19440569/pubmed" id="19440569" target="_blank">19440569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21165382">
<a name="21165382"></a>Chaplin AC, Curley MA, Wanless IR. Re: Recent case report of clozapine-induced acute hepatic failure. <i>Can J Gastroenterol</i>. 2010;24(12):739-741. doi:10.1155/2010/535026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/21165382/pubmed" id="21165382" target="_blank">21165382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9483262">
<a name="9483262"></a>Chatterton R. Eosinophilia after commencement of clozapine treatment. <i>Aust N Z J Psychiatry</i>. 1997;31(6):874-876. doi:10.3109/00048679709065515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9483262/pubmed" id="9483262" target="_blank">9483262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16928430">
<a name="16928430"></a>Chew ML, Mulsant BH, Pollock BG, et al. A model of anticholinergic activity of atypical antipsychotic medications. <i>Schizophr Res</i>. 2006;88(1-3):63-72. doi:10.1016/j.schres.2006.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16928430/pubmed" id="16928430" target="_blank">16928430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30478891">
<a name="30478891"></a>Cho J, Hayes RD, Jewell A, et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. <i>Acta Psychiatr Scand</i>. 2019;139(3):237-247. doi:10.1111/acps.12989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/30478891/pubmed" id="30478891" target="_blank">30478891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32036793">
<a name="32036793"></a>Chrétien B, Lelong-Boulouard V, Chantepie S, et al. Haematologic malignancies associated with clozapine <i>v.</i> all other antipsychotic agents: a pharmacovigilance study in VigiBase<sup>®</sup>. <i>Psychol Med</i>. 2021;51(9):1459-1466. doi:10.1017/S0033291720000161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32036793/pubmed" id="32036793" target="_blank">32036793</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21495734">
<a name="21495734"></a>Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. <i>Clin Drug Investig</i>. 2011;31(7):455-482. doi:10.2165/11589060-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/21495734/pubmed" id="21495734" target="_blank">21495734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28392207">
<a name="28392207"></a>Clark SR, Warren NS, Kim G, et al. Elevated clozapine levels associated with infection: A systematic review.<i> Schizophr Res.</i> 2017. pii: S0920-9964(17)30185-30188. doi: 10.1016/j.schres.2017.03.045.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28392207/pubmed" id="28392207" target="_blank">28392207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mayne.1">
<a name="Mayne.1"></a>Clozapine [prescribing information]. Greenville, NC: Mayne Pharma; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HLS.1">
<a name="HLS.1"></a>Clozaril (clozapine) [prescribing information]. Rosemont, PA: HLS Therapeutics (USA) Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HLS.1">
<a name="HLS.1"></a>Clozaril (clozapine) [prescribing information]. Rosemont, PA: HLS Therapeutics (USA) Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HLS.2">
<a name="HLS.2"></a>Clozaril (clozapine) [product monograph]. Etobicoke, Ontario, Canada: HLS Therapeutics Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29230675">
<a name="29230675"></a>Cohen D. Clozapine and gastrointestinal hypomotility. <i>CNS Drugs.</i> 2017;31(12):1083-1091. doi: 10.1007/s40263-017-0481-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29230675/pubmed" id="29230675" target="_blank">29230675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11483480">
<a name="11483480"></a>Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. <i>Br J Psychiatry</i>. 2001;179:167-171. doi:10.1192/bjp.179.2.167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11483480/pubmed" id="11483480" target="_blank">11483480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18052897">
<a name="18052897"></a>Corallo CE, Ernest D. Atypical neuroleptic malignant syndrome with long-term clozapine. <i>Crit Care Resusc</i>. 2007;9(4):338-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18052897/pubmed" id="18052897" target="_blank">18052897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19861668">
<a name="19861668"></a>Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents [published correction appears in <i>JAMA</i>. 2009;302(21):2322]. <i>JAMA</i>. 2009;302(16):1765-1773. doi:10.1001/jama.2009.1549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19861668/pubmed" id="19861668" target="_blank">19861668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16321730">
<a name="16321730"></a>Correll CU, Penzner JB, Parikh UH, et al, "Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents," <i>Child Adolesc Psych Clin N Am</i>, 2006, 15(1):177-206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16321730/pubmed" id="16321730" target="_blank">16321730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770500">
<a name="31770500"></a>Costa-Dookhan KA, Agarwal SM, Chintoh A, et al. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. <i>Expert Opin Drug Saf</i>. 2020;19(1):43-57. doi:10.1080/14740338.2020.1698545<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31770500/pubmed" id="31770500" target="_blank">31770500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955499">
<a name="29955499"></a>Crouse EL, Alastanos JN, Bozymski KM, Toscano RA. Dysphagia with second-generation antipsychotics: a case report and review of the literature. <i>Ment Health Clin</i>. 2018;7(2):56-64. doi:10.9740/mhc.2017.03.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29955499/pubmed" id="29955499" target="_blank">29955499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29345690">
<a name="29345690"></a>Datta T, Solomon AJ. Clozapine-induced myocarditis. <i>Oxf Med Case Reports</i>. 2018;2018(1):omx080. doi:10.1093/omcr/omx080<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29345690/pubmed" id="29345690" target="_blank">29345690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31123659">
<a name="31123659"></a>Davis EAK, Kelly DL. Clozapine-associated renal failure: a case report and literature review. <i>Ment Health Clin</i>. 2019;9(3):124-127. doi:10.9740/mhc.2019.05.124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31123659/pubmed" id="31123659" target="_blank">31123659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10852096">
<a name="10852096"></a>Davydov L, Botts SR. Clozapine-induced hypersalivation. <i>Ann Pharmacother</i>. 2000;34(5):662-665. doi:10.1345/aph.19259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10852096/pubmed" id="10852096" target="_blank">10852096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28883731">
<a name="28883731"></a>Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. <i>Neuropsychiatr Dis Treat</i>. 2017;13:2231-2241. doi:10.2147/NDT.S113099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28883731/pubmed" id="28883731" target="_blank">28883731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29796248">
<a name="29796248"></a>De Berardis D, Rapini G, Olivieri L, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. <i>Ther Adv Drug Saf</i>. 2018;9(5):237-256. doi:10.1177/2042098618756261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29796248/pubmed" id="29796248" target="_blank">29796248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22009159">
<a name="22009159"></a>De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. <i>Nat Rev Endocrinol</i>. 2011b;8(2):114-126. doi:10.1038/nrendo.2011.156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22009159/pubmed" id="22009159" target="_blank">22009159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20542667">
<a name="20542667"></a>De Hert M, Hudyana H, Dockx L, et al. Second-generation antipsychotics and constipation: a review of the literature. <i>Eur Psychiatry. </i>2011a;26(1):34-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20542667/pubmed" id="20542667" target="_blank">20542667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17346932">
<a name="17346932"></a>de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. <i>Schizophr Res</i>. 2007;92(1-3):95-102. doi:10.1016/j.schres.2007.01.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17346932/pubmed" id="17346932" target="_blank">17346932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dean.1">
<a name="Dean.1"></a>Dean L. Clozapine therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes. In: Pratt V, ed. <i>Medical Genetics Summaries</i>. Bethesda, MD: National Center for Biotechnology Information (US); 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32182485">
<a name="32182485"></a>Delgado A, Velosa J, Zhang J, Dursun SM, Kapczinski F, de Azevedo Cardoso T. Clozapine in bipolar disorder: a systematic review and meta-analysis. <i>J Psychiatr Res.</i> 2020;125:21-27. doi:10.1016/j.jpsychires.2020.02.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32182485/pubmed" id="32182485" target="_blank">32182485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30336807">
<a name="30336807"></a>DeRemer CE, Andrick BJ, Capito MD. Clozapine drug-induced pancreatitis of intermediate latency of onset confirmed by de-challenge and re-challenge . <i>Int J Clin Pharmacol Ther</i>. 2019;57(1):37-40. doi:10.5414/CP203314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/30336807/pubmed" id="30336807" target="_blank">30336807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15503744">
<a name="15503744"></a>Dewan V, Roth BA. Antipsychotic-induced QTc interval prolongation. <i>Can J Psychiatry</i>. 2004;49(9):646. doi:10.1177/070674370404900923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15503744/pubmed" id="15503744" target="_blank">15503744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29901563">
<a name="29901563"></a>Dimitri Valente G, Dusi N, Lasalvia A. An idiosyncratic, acute, systemic, and life-threatening adverse reaction in a young patient treated with clozapine: a case report. <i>J Clin Psychopharmacol</i>. 2018;38(4):387-389. doi:10.1097/JCP.0000000000000900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29901563/pubmed" id="29901563" target="_blank">29901563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590213">
<a name="25590213"></a>Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2015;100(2):363-370. doi:10.1210/jc.2014-3421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25590213/pubmed" id="25590213" target="_blank">25590213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26634131">
<a name="26634131"></a>Donizete da Costa F, Toledo da Silva Antonialli K, Dalgalarrondo P. Priapism and clozapine use in a patient with hypochondriacal delusional syndrome. <i>Oxf Med Case Reports</i>. 2015;2015(3):229-231. doi:10.1093/omcr/omv020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26634131/pubmed" id="26634131" target="_blank">26634131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24012072">
<a name="24012072"></a>Driver DI, Gogtay N, Rapoport JL. Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. <i>Child Adolesc Psychiatr Clin N Am</i>. 2013;22(4):539-555. doi:10.1016/j.chc.2013.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24012072/pubmed" id="24012072" target="_blank">24012072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15206669">
<a name="15206669"></a>Eap CB, Bender S, Jaquenoud Sirot E, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. <i>J Clin Psychopharmacol</i>. 2004;24(2):214-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15206669/pubmed" id="15206669" target="_blank">15206669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23278567">
<a name="23278567"></a>Ely SF, Neitzel AR, Gill JR. Fatal diabetic ketoacidosis and antipsychotic medication. <i>J Forensic Sci</i>. 2013;58(2):398-403. doi:10.1111/1556-4029.12044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23278567/pubmed" id="23278567" target="_blank">23278567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17414689">
<a name="17414689"></a>Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. <i>J Psychiatr Pract</i>. 2007;13(2):117-119. doi:10.1097/01.pra.0000265770.17871.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17414689/pubmed" id="17414689" target="_blank">17414689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30456745">
<a name="30456745"></a>Every-Palmer S, Inns SJ, Grant E, Ellis PM. Effects of clozapine on the gut: cross-sectional study of delayed gastric emptying and small and large intestinal dysmotility. <i>CNS Drugs</i>. 2019;33(1):81-91. doi:10.1007/s40263-018-0587-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/30456745/pubmed" id="30456745" target="_blank">30456745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27532076">
<a name="27532076"></a>Every-Palmer S, Nowitz M, Stanley J, et al. Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. <i>EBioMedicine.</i> 2016;5:125-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/27532076/pubmed" id="27532076" target="_blank">27532076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15280515">
<a name="15280515"></a>Farah RE, Makhoul NM, Farah RE, Shai MD. Fatal venous thromboembolism associated with antipsychotic therapy. <i>Ann Pharmacother</i>. 2004;38(9):1435-1438. doi:10.1345/aph.1E021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15280515/pubmed" id="15280515" target="_blank">15280515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jazz.1">
<a name="Jazz.1"></a>FazaClo (clozapine) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23279439">
<a name="23279439"></a>Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. <i>Eur J Neurol</i>. 2013;20(1):5-15. doi:10.1111/j.1468-1331.2012.03866.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23279439/pubmed" id="23279439" target="_blank">23279439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16182674">
<a name="16182674"></a>Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. <i>J Pediatr</i>. 2005;147(3):348-354. doi:10.1016/j.jpeds.2005.03.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16182674/pubmed" id="16182674" target="_blank">16182674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17314729">
<a name="17314729"></a>Findling RL, Frazier JA, Gerbino-Rosen B, et al, "Is There a Role for Clozapine in the Treatment of Children and Adolescents?" <i>J Am Acad Child Adolesc Psych</i>, 2007, 46(3):423-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17314729/pubmed" id="17314729" target="_blank">17314729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17109073">
<a name="17109073"></a>Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. <i>J Neural Transm (Vienna)</i>. 2007;114(2):273-280. doi:10.1007/s00702-006-0602-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17109073/pubmed" id="17109073" target="_blank">17109073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration. Coronavirus (COVID-19) Update: FDA provides update on patient access to certain REMS drugs during COVID-19 public health emergency. <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-update-patient-access-certain-rems-drugs-during-covid-19" target="_blank">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-update-patient-access-certain-rems-drugs-during-covid-1</a>9. Published March 22, 2020. Accessed March 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20702068">
<a name="20702068"></a>Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>Eur Neuropsychopharmacol</i>. 2011;21(8):621-645. doi:10.1016/j.euroneuro.2010.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20702068/pubmed" id="20702068" target="_blank">20702068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12544379">
<a name="12544379"></a>Frazier JA, Cohen LG, Jacobsen L, et al. Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. <i>J Clin Psychopharmacol</i>. 2003;23(1):87-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/12544379/pubmed" id="12544379" target="_blank">12544379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Freudenreich.2020">
<a name="Freudenreich.2020"></a>Freudenreich O, McEvoy J. Schizophrenia in adults: Guidelines for prescribing clozapine. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11206605">
<a name="11206605"></a>Freudenreich O, Goff DC. Colon perforation and peritonitis associated with clozapine. <i>J Clin Psychiatry</i>. 2000;61(12):950-951. doi:10.4088/jcp.v61n1210e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11206605/pubmed" id="11206605" target="_blank">11206605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17070675">
<a name="17070675"></a>Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S. Treating dopaminergic psychosis in Parkinson’s disease: structured review and meta-analysis. <i>Eur Neuropsychopharmacol</i>. 2007;17(3):165-171. doi:10.1016/j.euroneuro.2006.08.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17070675/pubmed" id="17070675" target="_blank">17070675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8968299">
<a name="8968299"></a>Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. <i>J Clin Psychiatry</i>. 1996;57(11):514-518. doi:10.4088/jcp.v57n1102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8968299/pubmed" id="8968299" target="_blank">8968299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11270919">
<a name="11270919"></a>Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. <i>J Clin Psychopharmacol</i>. 2001a;21(2):215-222. doi:10.1097/00004714-200104000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11270919/pubmed" id="11270919" target="_blank">11270919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11386494">
<a name="11386494"></a>Gaertner I, Gaertner HJ, Vonthein R, Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study.<i> J Clin</i>
<i>Psychopharmacol</i>. 2001b;21(3):305-310. doi:10.1097/00004714-200106000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11386494/pubmed" id="11386494" target="_blank">11386494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16804375">
<a name="16804375"></a>Gambassi G, Capurso S, Tarsitani P, Liperoti R, Bernabei R. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. <i>Aging Clin Exp Res</i>. 2006;18(3):266-270. doi:10.1007/BF03324659<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16804375/pubmed" id="16804375" target="_blank">16804375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24158020">
<a name="24158020"></a>Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. <i>J Clin Psychopharmacol</i>. 2014;34(1):109-123. doi:10.1097/JCP.0b013e3182a6096e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24158020/pubmed" id="24158020" target="_blank">24158020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759705">
<a name="18759705"></a>Gareri P, De Fazio P, Russo E, et al. The Safety of Clozapine in the Elderly. <i>Expert Opin Drug Saf</i>. 2008;7(5):525-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18759705/pubmed" id="18759705" target="_blank">18759705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17535043">
<a name="17535043"></a>Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G. Conventional and atypical antipsychotics in the elderly: a review.<i> Clin Drug Investig</i>. 2003;23(5):287-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17535043/pubmed" id="17535043" target="_blank">17535043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32494516">
<a name="32494516"></a>Garg A, Bath AS, Kalavakunta JK. Non-ischemic cardiomyopathy: a rare adverse effect of clozapine. <i>Cureus</i>. 2020;12(4):e7901. doi:10.7759/cureus.7901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32494516/pubmed" id="32494516" target="_blank">32494516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Gen-Clozapine [product monograph]. Etobicoke, Ontario, Canada: Mylan Pharmaceuticals ULC; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16175107">
<a name="16175107"></a>Gerbino-Rosen G, Roofeh D, Tompkins DA, et al, "Hematological Adverse Events in Clozapine-Treated Children and Adolescents," <i>J Am Acad Child Adolesc Psychiatry</i>, 2005, 44(10):1024-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16175107/pubmed" id="16175107" target="_blank">16175107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8866742">
<a name="8866742"></a>Gerlach J, Lublin H, Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. <i>Neuropsychopharmacology</i>. 1996;14(3 suppl):35S-39S. doi:10.1016/0893-133X(95)00203-P<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8866742/pubmed" id="8866742" target="_blank">8866742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7961551">
<a name="7961551"></a>Gerlach J, Peacock L. Motor and mental side effects of clozapine. <i>J Clin Psychiatry</i>. 1994;55 Suppl B:107-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/7961551/pubmed" id="7961551" target="_blank">7961551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548409">
<a name="17548409"></a>Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. <i>Ann Intern Med</i>. 2007;146(11):775-786. doi:10.7326/0003-4819-146-11-200706050-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17548409/pubmed" id="17548409" target="_blank">17548409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22841129">
<a name="22841129"></a>Goikolea JM, Colom F, Capapey J, et al. Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania. <i>Eur Neuropsychopharmacol</i>. 2013;23(4):305-316. doi:10.1016/j.euroneuro.2012.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22841129/pubmed" id="22841129" target="_blank">22841129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25187353">
<a name="25187353"></a>Goldstein JI, Jarskog LF, Hilliard C, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. <i>Nat Commun</i>. 2014;5:4757. doi:10.1038/ncomms5757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25187353/pubmed" id="25187353" target="_blank">25187353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29983780">
<a name="29983780"></a>Gorup E, Rifel J, Petek Šter M. Anticholinergic burden and most common anticholinergic-acting medicines in older general practice patients. <i>Zdr Varst</i>. 2018;57(3):140-147. doi:10.2478/sjph-2018-0018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29983780/pubmed" id="29983780" target="_blank">29983780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22216049">
<a name="22216049"></a>Goyal N, Praharaj SK, Desarkar P, Nizamie H. Electroencephalographic abnormalities in clozapine-treated patients: a cross-sectional study. <i>Psychiatry Investig</i>. 2011;8(4):372-376. doi:10.4306/pi.2011.8.4.372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22216049/pubmed" id="22216049" target="_blank">22216049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10831480">
<a name="10831480"></a>Green AI, Tohen M, Patel JK, et al. Clozapine in the treatment of refractory psychotic mania. <i>Am J Psychiatry</i>. 2000;157(6):982-986. doi: 10.1176/appi.ajp.157.6.982.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10831480/pubmed" id="10831480" target="_blank">10831480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26118746">
<a name="26118746"></a>Grover S, Hazari N, Chakrabarti S, Avasthi A. Association of clozapine with seizures: a brief report involving 222 patients prescribed clozapine. <i>East Asian Arch Psychiatry</i>. 2015;25(2):73-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26118746/pubmed" id="26118746" target="_blank">26118746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19347775">
<a name="19347775"></a>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. <i>World J Biol Psychiatry</i>. 2009;10(2):85-116. doi:10.1080/15622970902823202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19347775/pubmed" id="19347775" target="_blank">19347775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21790209">
<a name="21790209"></a>Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. <i>CNS Drugs</i>. 2011;25(8):659-671. doi:10.2165/11591710-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/21790209/pubmed" id="21790209" target="_blank">21790209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9864080">
<a name="9864080"></a>Guitton C, Abbar M, Kinowski JM, et al. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. <i>J Clin Psychopharmacol. </i>1998;18(6):470-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9864080/pubmed" id="9864080" target="_blank">9864080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35178700">
<a name="35178700"></a>Gurrera RJ, Gearin PF, Love J, et al. Recognition and management of clozapine adverse effects: a systematic review and qualitative synthesis. <i>Acta Psychiatr Scand</i>. 2022;145(5):423-441. doi:10.1111/acps.13406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/35178700/pubmed" id="35178700" target="_blank">35178700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26848787">
<a name="26848787"></a>Gurrera RJ, Parlee AC, Perry NL. Aspiration pneumonia, an unappreciated risk of clozapine treatment. <i>J Clin Psychopharmacol</i>. 2016;36(2):174-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26848787/pubmed" id="26848787" target="_blank">26848787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10791380">
<a name="10791380"></a>Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. <i>Lancet</i>. 2000;355(9210):1155-1156. doi:10.1016/S0140-6736(00)02066-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10791380/pubmed" id="10791380" target="_blank">10791380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18941580">
<a name="18941580"></a>Hansen A, Bi P, Nitschke M, Ryan P, Pisaniello D, Tucker G. The effect of heat waves on mental health in a temperate Australian city. <i>Environ Health Perspect</i>. 2008;116(10):1369-1375. doi:10.1289/ehp.11339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18941580/pubmed" id="18941580" target="_blank">18941580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22834451">
<a name="22834451"></a>Hasan A, Falkai P, Wobrock T, et al; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World J Biol Psychiatry</i>. 2012;13(5):318-378. doi: 10.3109/15622975.2012.696143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22834451/pubmed" id="22834451" target="_blank">22834451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25168784">
<a name="25168784"></a>Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. <i>CNS Drugs</i>. 2014;28(10):887-920. doi:10.1007/s40263-014-0196-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25168784/pubmed" id="25168784" target="_blank">25168784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25154620">
<a name="25154620"></a>Hayes RD, Downs J, Chang CK, et al. The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. <i>Schizophr Bull</i>. 2015;41(3):644-655. doi:10.1093/schbul/sbu120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25154620/pubmed" id="25154620" target="_blank">25154620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HealthCanada.1">
<a name="HealthCanada.1"></a>Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Atypical antipsychotics - assessing the potential risk of sleep apnoea. Health Canada website. <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html" target="_blank">https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html</a>. Published August 16, 2016. Accessed August 23, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12973403">
<a name="12973403"></a>Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. <i>Drugs Today (Barc)</i>. 2003;39(7):551-557. doi:10.1358/dot.2003.39.7.799445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/12973403/pubmed" id="12973403" target="_blank">12973403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11603884">
<a name="11603884"></a>Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. <i>J Clin Psychiatry</i>. 2001;62 Suppl 23:39-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11603884/pubmed" id="11603884" target="_blank">11603884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16187768">
<a name="16187768"></a>Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. <i>J Clin Psychiatry</i>. 2005;66(9):1116-1121. doi:10.4088/jcp.v66n0905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16187768/pubmed" id="16187768" target="_blank">16187768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095482">
<a name="29095482"></a>Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. <i>J Am Geriatr Soc</i>. 2017;65(12):2580-2586. doi:10.1111/jgs.15066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29095482/pubmed" id="29095482" target="_blank">29095482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi: 10.1055/s-0043-116492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8633706">
<a name="8633706"></a>Hinze-Selch D, Becker EW, Stein G, Schreiber W, Pollmächer T. Clozapine-induced parotitis: an immunological cause? <i>Am J Psychiatry</i>. 1996;153(6):840. doi:10.1176/ajp.153.6.840a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8633706/pubmed" id="8633706" target="_blank">8633706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27074342">
<a name="27074342"></a>Hoffmann MS, Oliveira LM, Lobato MI, Belmonte-de-Abreu P. Heat stroke during long-term clozapine treatment: should we be concerned about hot weather? <i>Trends Psychiatry Psychother</i>. 2016;38(1):56-59. doi:10.1590/2237-6089-2015-0066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/27074342/pubmed" id="27074342" target="_blank">27074342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10074877">
<a name="10074877"></a>Howanitz E, Pardo M, Smelson DA, et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. <i>J Clin Psychiatry</i>. 1999;60(1):41-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10074877/pubmed" id="10074877" target="_blank">10074877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10671383">
<a name="10671383"></a>Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. <i>Am J Psychiatry</i>. 2000;157(2):172-178. doi:10.1176/appi.ajp.157.2.172<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10671383/pubmed" id="10671383" target="_blank">10671383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19675512">
<a name="19675512"></a>Hrdlicka M, Zedkova I, Blatny M, Urbanek T. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. <i>Neuro Endocrinol Lett</i>. 2009;30(2):256-261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19675512/pubmed" id="19675512" target="_blank">19675512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29924506">
<a name="29924506"></a>Hsu JH, Mulsant BH, Lenze EJ, et al. Clinical predictors of extrapyramidal symptoms associated with aripiprazole augmentation for the treatment of late-life depression in a randomized controlled trial. <i>J Clin Psychiatry</i>. 2018;79(4):17m11764. doi:10.4088/JCP.17m11764<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29924506/pubmed" id="29924506" target="_blank">29924506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9241012">
<a name="9241012"></a>Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. <i>J Clin Psychopharmacol</i>. 1997;17(4):314-317. doi:10.1097/00004714-199708000-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9241012/pubmed" id="9241012" target="_blank">9241012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28106314">
<a name="28106314"></a>Hung YP, Wang CS, Yen CN, et al. Role of cytokine changes in clozapine-induced fever: a cohort prospective study. <i>Psychiatry Clin Neurosci</i>. 2017;71(6):395-402. doi:10.1111/pcn.12508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28106314/pubmed" id="28106314" target="_blank">28106314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29636684">
<a name="29636684"></a>Imaz ML, Oriolo G, Torra M, Soy D, García-Esteve L, Martin-Santos R. Clozapine use during pregnancy and lactation: a case-series report. <i>Front Pharmacol.</i> 2018;9:264. doi:10.3389/fphar.2018.00264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29636684/pubmed" id="29636684" target="_blank">29636684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25140533">
<a name="25140533"></a>Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. <i>PLoS One</i>. 2014;9(8):e105376. doi:10.1371/journal.pone.0105376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25140533/pubmed" id="25140533" target="_blank">25140533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33863375">
<a name="33863375"></a>Jaguga F. Clozapine-induced stuttering in the absence of known risk factors: a case report. <i>J Med Case Rep</i>. 2021;15(1):174. doi:10.1186/s13256-021-02803-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/33863375/pubmed" id="33863375" target="_blank">33863375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24416588">
<a name="24416588"></a>Jones ME, Campbell G, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in users of olanzapine and other antipsychotics: a study with the general practice research database. <i>Cardiovasc Psychiatry Neurol</i>. 2013;2013:647476. doi:10.1155/2013/647476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24416588/pubmed" id="24416588" target="_blank">24416588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193526">
<a name="22193526"></a>Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. <i>Am J Psychiatry</i>. 2012;169(1):71-79. doi:10.1176/appi.ajp.2011.11030347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22193526/pubmed" id="22193526" target="_blank">22193526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25553232">
<a name="25553232"></a>Kane JP, O'Neill FA. Clozapine-induced liver injury and pleural effusion. <i>Ment Illn</i>. 2014;6(2):5403. doi:10.4081/mi.2014.5403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25553232/pubmed" id="25553232" target="_blank">25553232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10901343">
<a name="10901343"></a>Kang UG, Kwon JS, Ahn YM, et al. Electrocardiographic abnormalities in patients treated with clozapine. <i>J Clin Psychiatry</i>. 2000;61(6):441-446. doi:10.4088/jcp.v61n0609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10901343/pubmed" id="10901343" target="_blank">10901343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32109805">
<a name="32109805"></a>Kanniah G, Kumar S. Clozapine associated cardiotoxicity: Issues, challenges and way forward. <i>Asian J Psychiatr</i>. 2020;50:101950. doi:10.1016/j.ajp.2020.101950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32109805/pubmed" id="32109805" target="_blank">32109805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15142392">
<a name="15142392"></a>Kant R, Chalansani R, Chengappa KN, et al, "The Off-Label Use of Clozapine in Adolescents With Bipolar Disorder, Intermittent Explosive Disorder, or Posttraumatic Stress Disorder," <i>J Child Adolesc Psychopharmacol</i>, 2004, 14(1):57-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15142392/pubmed" id="15142392" target="_blank">15142392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29092658">
<a name="29092658"></a>Kaplan AM, Pitts WB, Ahmed I. An unexpected circumstance: acute dystonic reaction in the setting of clozapine administration. <i>J Pharm Pract</i>. 2019;32(1):103-105. doi:10.1177/0897190017737696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29092658/pubmed" id="29092658" target="_blank">29092658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15107195">
<a name="15107195"></a>Kerwin RW, Osborne S, Sainz-Fuertes R. Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management. <i>J Psychopharmacol</i>. 2004;18(1):121-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15107195/pubmed" id="15107195" target="_blank">15107195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10584719">
<a name="10584719"></a>Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. <i>Lancet</i>. 1999;354(9193):1841-1845. doi:10.1016/s0140-6736(99)10385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10584719/pubmed" id="10584719" target="_blank">10584719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25969624">
<a name="25969624"></a>Kirpekar CV, Faye DA, Gawande S, Tadke R, Bhave SH. Clozapine induced supra ventricular tachycardia. <i>Indian J Psychol Med</i>. 2015;37(2):254-255. doi:10.4103/0253-7176.155685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25969624/pubmed" id="25969624" target="_blank">25969624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33866283">
<a name="33866283"></a>Kitagawa K, Uekusa S, Matsuo K, et al. Risk factors for clozapine-induced central nervous system abnormalities in Japanese patients with treatment-resistant schizophrenia. <i>Asian J Psychiatr</i>. 2021;60:102652. doi:10.1016/j.ajp.2021.102652<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/33866283/pubmed" id="33866283" target="_blank">33866283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22257975">
<a name="22257975"></a>Kluge M, Himmerich H, Wehmeier PM, et al. Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine. <i>Schizophr Res</i>. 2012;135(1-3):123-127. doi:10.1016/j.schres.2011.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22257975/pubmed" id="22257975" target="_blank">22257975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18835660">
<a name="18835660"></a>Kluge M, Schuld A, Schacht A, et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. <i>Psychoneuroendocrinology</i>. 2009;34(1):118-128. doi:10.1016/j.psyneuen.2008.08.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18835660/pubmed" id="18835660" target="_blank">18835660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29548760">
<a name="29548760"></a>Knoph KN, Morgan RJ 3rd, Palmer BA, et al. Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review. <i>Schizophr Res</i>. 2018;199:17-30. doi:10.1016/j.schres.2018.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29548760/pubmed" id="29548760" target="_blank">29548760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12766935">
<a name="12766935"></a>Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome--a case review. <i>Hum Psychopharmacol</i>. 2003;18(4):301-309. doi:10.1002/hup.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/12766935/pubmed" id="12766935" target="_blank">12766935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19126823">
<a name="19126823"></a>Kohen I, Afzal N, Hussain S, Manu P. Increases in C-reactive protein may predict recurrence of clozapine-induced fever. <i>Ann Pharmacother</i>. 2009;43(1):143-146. doi:10.1345/aph.1L467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19126823/pubmed" id="19126823" target="_blank">19126823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11747852">
<a name="11747852"></a>Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. <i>Am J Med</i>. 2001;111(9):716-723. doi:10.1016/s0002-9343(01)01000-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11747852/pubmed" id="11747852" target="_blank">11747852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33552171">
<a name="33552171"></a>Komaryk A, Elbe D, Burgess L. Retrospective review of clozapine use in children and adolescents. <i>J Can Acad Child Adolesc Psychiatry</i>. 2021;30(1):36-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/33552171/pubmed" id="33552171" target="_blank">33552171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9704170">
<a name="9704170"></a>Koren W, Koren E, Nacasch N, Ehrenfeld M, Gur H. Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes. <i>Clin Neuropharmacol</i>. 1998;21(4):262-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9704170/pubmed" id="9704170" target="_blank">9704170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16321728">
<a name="16321728"></a>Kranzler HN, Kester HM, Gerbino-Rosen G, et al, "Treatment-Refractory Schizophrenia in Children and Adolescents: An Update on Clozapine and Other Pharmacologic Interventions," <i>Child Adolesc Psychiatr Clin N Am</i>, 2006, 15(1):135-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16321728/pubmed" id="16321728" target="_blank">16321728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15608544">
<a name="15608544"></a>Kranzler H, Roofeh D, Gerbino-Rosen G, et al, "Clozapine: Its Impact on Aggressive Behavior Among Children and Adolescents With Schizophrenia," <i>J Am Acad Child Adolesc Psychiatry</i>, 2005, 44(1):55-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15608544/pubmed" id="15608544" target="_blank">15608544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24129841">
<a name="24129841"></a>Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS. Atypical antipsychotics for psychosis in adolescents. <i>Cochrane Database Syst Rev</i>. 2013;(10):CD009582.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24129841/pubmed" id="24129841" target="_blank">24129841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31179433">
<a name="31179433"></a>Kumar P, Mishra DK, Mishra N, Ahuja S, Raghuvanshi G, Niranjan V. Acute onset clozapine-induced hyperglycaemia: a case report. <i>Gen Psychiatr</i>. 2019;32(2):e100045. doi:10.1136/gpsych-2018-100045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31179433/pubmed" id="31179433" target="_blank">31179433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32304306">
<a name="32304306"></a>Kumar R, Sharma A, Kaur N, Singh A, Chhabra M, Sharma R. A case report on clozapine-induced ventricular ectopics: a fatal adverse drug reaction. <i>J Basic Clin Physiol Pharmacol</i>. 2020;31(3):/j/jbcpp.2020.31.issue-3/jbcpp-2019-0339/jbcpp-2019-0339.xml. doi:10.1515/jbcpp-2019-0339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32304306/pubmed" id="32304306" target="_blank">32304306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8956674">
<a name="8956674"></a>Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. <i>Arch Gen Psychiatry</i>. 1996;53(12):1090-1097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8956674/pubmed" id="8956674" target="_blank">8956674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17651705">
<a name="17651705"></a>Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. <i>Biol Psychiatry</i>. 2008;63(5):524-529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17651705/pubmed" id="17651705" target="_blank">17651705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174785">
<a name="16174785"></a>Kwok JS, Chan TY. Recurrent heat-related illnesses during antipsychotic treatment. <i>Ann Pharmacother</i>. 2005;39(11):1940-1942. doi:10.1345/aph.1G130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16174785/pubmed" id="16174785" target="_blank">16174785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31335444">
<a name="31335444"></a>Lally J, OʼConnor N, Fullam S, et al. Rechallenge following clozapine-associated eosinophilia: a case report and literature review. <i>J Clin Psychopharmacol</i>. 2019;39(5):504-506. doi:10.1097/JCP.0000000000001079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31335444/pubmed" id="31335444" target="_blank">31335444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24016844">
<a name="24016844"></a>Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbæk G. Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>Am J Geriatr Psychiatry</i>. 2014;22(4):321-331. doi:10.1016/j.jagp.2013.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24016844/pubmed" id="24016844" target="_blank">24016844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi: 10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16166184">
<a name="16166184"></a>Layton D, Harris S, Wilton LV, Shakir SA. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. <i>J Psychopharmacol</i>. 2005;19(5):473-482. doi:10.1177/0269881105056524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16166184/pubmed" id="16166184" target="_blank">16166184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17712102">
<a name="17712102"></a>Lee HB, Hanner JA, Yokley JL, Appleby B, Hurowitz L, Lyketsos CG. Clozapine for treatment-resistant agitation in dementia. <i>J Geriatr Psychiatry Neurol</i>. 2007;20(3):178-182. doi:10.1177/0891988707303335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17712102/pubmed" id="17712102" target="_blank">17712102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26720509">
<a name="26720509"></a>Lee J, Takeuchi H, Fervaha G, et al. Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. <i>Can J Psychiatry</i>. 2015;60(11):515-522. doi:10.1177/070674371506001107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26720509/pubmed" id="26720509" target="_blank">26720509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7961582">
<a name="7961582"></a>Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. <i>J Clin Psychiatry</i>. 1994;55 Suppl B:82-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/7961582/pubmed" id="7961582" target="_blank">7961582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30767710">
<a name="30767710"></a>Legge SE, Walters JT. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. <i>Pharmacogenomics</i>. 2019;20(4):279-290. doi:10.2217/pgs-2018-0188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/30767710/pubmed" id="30767710" target="_blank">30767710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15000267">
<a name="15000267"></a>Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association, Steering Committee on Practice Guidelines. Practice guidelines for the treatment of patients with schizophrenia, second edition. <i>Am J Psychiatry</i>. 2004;161(2 suppl):1-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15000267/pubmed" id="15000267" target="_blank">15000267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23146619">
<a name="23146619"></a>Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, García M, Aguirre C. Antipsychotics and seizures: higher risk with atypicals? <i>Seizure</i>. 2013;22(2):141-143. doi:10.1016/j.seizure.2012.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23146619/pubmed" id="23146619" target="_blank">23146619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24619948">
<a name="24619948"></a>Leung JG, Nelson S, Takala CR, et al. Infection and inflammation leading to clozapine toxicity and intensive care: a case series.<i> Ann Pharmacother.</i> 2014;48(6):801-805. doi: 10.1177/1060028014526701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24619948/pubmed" id="24619948" target="_blank">24619948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849294">
<a name="18849294"></a>Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. S<i>chizophr Bull</i>. 2010;36(3):624-632. doi:10.1093/schbul/sbn120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18849294/pubmed" id="18849294" target="_blank">18849294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19995222">
<a name="19995222"></a>Li CR, Chung YC, Park TW, et al. Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug. <i>World J Biol Psychiatry</i>. 2009;10(4 Pt 3):919-924. doi:10.1080/15622970802481895<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19995222/pubmed" id="19995222" target="_blank">19995222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9483266">
<a name="9483266"></a>Li JK, Yeung VT, Leung CM, et al. Clozapine: a mimicry of phaeochromocytoma. <i>Aust N Z J Psychiatry</i>. 1997;31(6):889-891. doi:10.3109/00048679709065519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9483266/pubmed" id="9483266" target="_blank">9483266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25346322">
<a name="25346322"></a>Li X-B, Tang Y-L, Wang C-Y, et al. Clozapine for treatment-resistant bipolar disorder: A systematic review. <i>Bipolar Disorders.</i> 2015;17:235-247. doi: 10.1111/bdi.12272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25346322/pubmed" id="25346322" target="_blank">25346322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32474068">
<a name="32474068"></a>Liu CL, Maruf AA, Bousman CA. Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: a pharmacovigilance database study. <i>Psychiatry Res</i>. 2020;290:113048. doi:10.1016/j.psychres.2020.113048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32474068/pubmed" id="32474068" target="_blank">32474068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9555602">
<a name="9555602"></a>Low RA Jr, Fuller MA, Popli A. Clozapine induced atrial fibrillation. <i>J Clin Psychopharmacol</i>. 1998;18(2):170. doi:10.1097/00004714-199804000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9555602/pubmed" id="9555602" target="_blank">9555602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20233914">
<a name="20233914"></a>Lowe EJ and Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. <i>Ann Pharmacother.</i> 2010; 44(4):727-732.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20233914/pubmed" id="20233914" target="_blank">20233914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35693728">
<a name="35693728"></a>Ma SM, Lim J, Jiang C, Luca L. Esophagitis after clozapine use in a 61-year-old woman with refractory schizophrenia. <i>Case Rep Psychiatry</i>. 2022;2022:7033038. doi:10.1155/2022/7033038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/35693728/pubmed" id="35693728" target="_blank">35693728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34991402">
<a name="34991402"></a>Mace S, Dzahini O, Cornelius V, Langerman H, Oloyede E, Taylor D. Incident infection during the first year of treatment - a comparison of clozapine and paliperidone palmitate long-acting injection. <i>J Psychopharmacol</i>. 2022;36(2):232-237. doi:10.1177/02698811211058973<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/34991402/pubmed" id="34991402" target="_blank">34991402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15138897">
<a name="15138897"></a>Maddalena AS, Fox M, Hofmann M, et al. Esophageal dysfunction on psychotropic medication. A case report and literature review. <i>Pharmacopsychiatry</i>. 2004;37(3):134-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15138897/pubmed" id="15138897" target="_blank">15138897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mady.1">
<a name="Mady.1"></a>Mady SP and Wax P, "Clozapine Intoxication in a Young Child," <i>Vet Hum Toxicol</i>, 1993, 35(4):338.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23510445">
<a name="23510445"></a>Maher KN, Tan M, Tossell JW, et al. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. <i>J Child Adolesc Psychopharmacol</i>. 2013;23(2):110‐116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23510445/pubmed" id="23510445" target="_blank">23510445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15285957">
<a name="15285957"></a>Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. <i>Am J Psychiatry</i>. 2004;161(8):1334-1349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15285957/pubmed" id="15285957" target="_blank">15285957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10335669">
<a name="10335669"></a>Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. <i>J Clin Psychiatry</i>. 1999;60(suppl 8):29-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10335669/pubmed" id="10335669" target="_blank">10335669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21772649">
<a name="21772649"></a>Majumder P, Chadda RK, Goyal P, Mittal A, Kumar N. Clozapine induced eosinophilia. <i>Indian J Psychiatry</i>. 2011;53(2):152-153. doi:10.4103/0019-5545.82546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/21772649/pubmed" id="21772649" target="_blank">21772649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29505490">
<a name="29505490"></a>Manu P, Lapitskaya Y, Shaikh A, Nielsen J. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. <i>Am J Ther</i>. 2018;25(2):e218-e223. doi:10.1097/MJT.0000000000000715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29505490/pubmed" id="29505490" target="_blank">29505490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8078987">
<a name="8078987"></a>Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR. The side-effects of clozapine: a four year follow-up study. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 1994;18(3):537-544. doi:10.1016/0278-5846(94)90010-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8078987/pubmed" id="8078987" target="_blank">8078987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12190212">
<a name="12190212"></a>Martinez M, Devenport L, Saussy J, Martinez J. Drug-associated heat stroke. <i>South Med J</i>. 2002;95(8):799-802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/12190212/pubmed" id="12190212" target="_blank">12190212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25786075">
<a name="25786075"></a>Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. <i>JAMA Psychiatry</i>. 2015;72(5):438-445. doi:10.1001/jamapsychiatry.2014.3018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25786075/pubmed" id="25786075" target="_blank">25786075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7962688">
<a name="7962688"></a>McCarthy RH, Terkelsen KG. Esophageal dysfunction in two patients after clozapine treatment. <i>J Clin Psychopharmacol</i>. 1994;14(4):281-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/7962688/pubmed" id="7962688" target="_blank">7962688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17195735">
<a name="17195735"></a>McClellan J, Kowatch R, Findling RL, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(1):107-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17195735/pubmed" id="17195735" target="_blank">17195735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29360288">
<a name="29360288"></a>McCollum B, Barclay J, de Leon J. Unexpected falls during clozapine treatment explained by myoclonus. <i>Prim Care Companion CNS Disord</i>. 2018;20(1):17l02151. doi:10.4088/PCC.17l02151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29360288/pubmed" id="29360288" target="_blank">29360288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27704220">
<a name="27704220"></a>Mehta TM, Van Lieshout RJ. A review of the safety of clozapine during pregnancy and lactation. <i>Arch Womens Ment Health.</i> 2017;20(1):1-9. doi:10.1007/s00737-016-0670-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/27704220/pubmed" id="27704220" target="_blank">27704220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15643098">
<a name="15643098"></a>Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. <i>J Clin Psychopharmacol</i>. 2005;25(1):32-41. doi:10.1097/01.jcp.0000150217.51433.9f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15643098/pubmed" id="15643098" target="_blank">15643098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32815018">
<a name="32815018"></a>Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. <i>Ann Hematol</i>. 2020;99(11):2477-2482. doi:10.1007/s00277-020-04215-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32815018/pubmed" id="32815018" target="_blank">32815018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16606910">
<a name="16606910"></a>Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: Evaluation and treatment of depression, psychosis and dementia in Parkinson disease (an evidence-based review); Report of the Quality Standards subcommittee of the American Academy of Neurology. <i>Am Acad Neurol. </i>2006; 66:996-1002. doi: 10.1212/01.wnl.0000215428.46057.3d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16606910/pubmed" id="16606910" target="_blank">16606910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32815018">
<a name="32815018"></a>Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. <i>Ann Hematol</i>. 2020;99(11):2477-2482. doi:10.1007/s00277-020-04215-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32815018/pubmed" id="32815018" target="_blank">32815018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29991947">
<a name="29991947"></a>Moazez C, Rudha Y, Narang N, Younger T. A rare presentation of clozapine-induced DRESS syndrome. <i>Case Rep Med</i>. 2018;2018:1346351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29991947/pubmed" id="29991947" target="_blank">29991947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10831019">
<a name="10831019"></a>Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. <i>J Clin Psychopharmacol</i>. 2000;20(3):325-327. doi:10.1097/00004714-200006000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10831019/pubmed" id="10831019" target="_blank">10831019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670542">
<a name="32670542"></a>Moncrieff J, Gupta S, Horowitz MA. Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder. <i>Ther Adv Psychopharmacol</i>. Published online July 6, 2020. doi:10.1177/2045125320937910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32670542/pubmed" id="32670542" target="_blank">32670542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34167790">
<a name="34167790"></a>Monteleone F, Gonçalves M, Fonseca L, et al. Clozapine-induced eosinophilia: a case report. <i>Rev Colomb Psiquiatr (Engl Ed)</i>. Published online June 21, 2021. doi:10.1016/j.rcp.2021.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/34167790/pubmed" id="34167790" target="_blank">34167790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319699">
<a name="15319699"></a>Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. <i>Clin Neuropharmacol</i>. 2004;27(4):153-156. doi:10.1097/01.wnf.0000136891.17006.ec<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15319699/pubmed" id="15319699" target="_blank">15319699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102845">
<a name="8102845"></a>Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. <i>Arch Gen Psychiatry</i>. 1993;50(9):723-733. doi:10.1001/archpsyc.1993.01820210057007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8102845/pubmed" id="8102845" target="_blank">8102845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20187598">
<a name="20187598"></a>Muench J, Hamer AM. Adverse effects of antipsychotic medications. <i>Am Fam Physician</i>. 2010;81(5):617-622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20187598/pubmed" id="20187598" target="_blank">20187598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32698608">
<a name="32698608"></a>Myles H, Large M. Considering the impact of viral illness on the aetiology of clozapine myocarditis. <i>Aust N Z J Psychiatry</i>. 2021;55(2):226. doi:10.1177/0004867420945793<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32698608/pubmed" id="32698608" target="_blank">32698608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29786829">
<a name="29786829"></a>Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. <i>Acta Psychiatr Scand</i>. 2018;138(2):101-109. doi: 10.1111/acps.12898.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29786829/pubmed" id="29786829" target="_blank">29786829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31718230">
<a name="31718230"></a>Nakajima N, Misawa F, Fujii Y, Takeuchi H. Clozapine-related gastrointestinal perforation: four case reports. <i>Aust N Z J Psychiatry</i>. 2020;54(5):541-542. doi:10.1177/0004867419887231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31718230/pubmed" id="31718230" target="_blank">31718230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28099349">
<a name="28099349"></a>Nanasawa H, Sako A, Mitsutsuka T, et al. Development of diabetes mellitus associated with quetiapine: a case series. <i>Medicine (Baltimore)</i>. 2017;96(3):e5900. doi:10.1097/MD.0000000000005900<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28099349/pubmed" id="28099349" target="_blank">28099349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26065063">
<a name="26065063"></a>National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health. Psychosis and schizophrenia in children and young people: recognition and management. 2013. https://www.nice.org.uk/guidance/cg155
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26065063/pubmed" id="26065063" target="_blank">26065063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998156">
<a name="15998156"></a>Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. <i>CNS Drugs</i>. 2005;19 Suppl 1:1-93. doi:10.2165/00023210-200519001-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15998156/pubmed" id="15998156" target="_blank">15998156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31203441">
<a name="31203441"></a>Nguyen T, Mordecai J, Watt F, Frayne J. Obstetric and neonatal outcomes of clozapine exposure in pregnancy: a consecutive case series. <i>Arch Womens Ment Health.</i> 2020;23(3):441-445. doi:10.1007/s00737-019-00985-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31203441/pubmed" id="31203441" target="_blank">31203441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nielsen.1">
<a name="Nielsen.1"></a>Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided? <i>J Clin Psych.</i> 2013;74(6): 603-613.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22854034">
<a name="22854034"></a>Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. <i>Can J Psychiatry</i>. 2012;57(8):512-518. doi:10.1177/070674371205700810<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22854034/pubmed" id="22854034" target="_blank">22854034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14565800">
<a name="14565800"></a>O'Neill JL, Remington TL. Drug-induced esophageal injuries and dysphagia. <i>Ann Pharmacother</i>. 2003;37(11):1675-1684. doi:10.1345/aph.1D056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/14565800/pubmed" id="14565800" target="_blank">14565800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17012695">
<a name="17012695"></a>Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. <i>Am J Psychiatry</i>. 2006;163(10):1821-1825. doi:10.1176/ajp.2006.163.10.1821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17012695/pubmed" id="17012695" target="_blank">17012695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28938913">
<a name="28938913"></a>Osterman MT, Foley C, Matthias I. Clozapine-induced acute gastrointestinal necrosis: a case report. <i>J Med Case Rep</i>. 2017;11(1):270. doi:10.1186/s13256-017-1447-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28938913/pubmed" id="28938913" target="_blank">28938913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11763009">
<a name="11763009"></a>Ozdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C--&gt;A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. <i>J Clin Psychopharmacol</i>. 2001;21(6):603-607.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11763009/pubmed" id="11763009" target="_blank">11763009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18796423">
<a name="18796423"></a>Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. <i>Am J Health Syst Pharm</i>.2008;65(19):1825-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18796423/pubmed" id="18796423" target="_blank">18796423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19512984">
<a name="19512984"></a>Papazisis G, Tzellos T, Tahmatzidis D, Dolianitis K, Kouvelas D. Late-onset clozapine-induced hypothermia accompanied by electrocardiogram Osborn waves. <i>J Clin Psychopharmacol</i>. 2009;29(2):183-185. doi:10.1097/JCP.0b013e31819a6a0d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19512984/pubmed" id="19512984" target="_blank">19512984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18452342">
<a name="18452342"></a>Palmer SE, McLean RM, Ellis PM, et al. Life-Threatening Clozapine-Induced Gastrointestinal Hypomotility: An Analysis of 102 Cases. <i>J Clin Psychiatry</i>. 2008;69(5):759-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18452342/pubmed" id="18452342" target="_blank">18452342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31347436">
<a name="31347436"></a>Pardis P, Remington G, Panda R, Lemez M, Agid O. Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review. <i>J Psychopharmacol</i>. 2019;33(10):1187-1198. doi:10.1177/0269881119862535<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31347436/pubmed" id="31347436" target="_blank">31347436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10072410">
<a name="10072410"></a>Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. <i>NEJM. </i>1999;340:757-763. doi: 10.1056/NEJM199903113401003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10072410/pubmed" id="10072410" target="_blank">10072410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31351758">
<a name="31351758"></a>Patel RK, Moore AM, Piper S, et al. Clozapine and cardiotoxicity - a guide for psychiatrists written by cardiologists. <i>Psychiatry Res</i>. 2019;282:112491. doi:10.1016/j.psychres.2019.112491<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31351758/pubmed" id="31351758" target="_blank">31351758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31325958">
<a name="31325958"></a>Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. <i>BMC Neurol</i>. 2019;19(1):174. doi:10.1186/s12883-019-1385-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31325958/pubmed" id="31325958" target="_blank">31325958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7962689">
<a name="7962689"></a>Pearlman C. Clozapine, nocturnal sialorrhea, and choking. <i>J Clin Psychopharmacol</i>. 1994;14(4):283. doi:10.1097/00004714-199408000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/7962689/pubmed" id="7962689" target="_blank">7962689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9735957">
<a name="9735957"></a>Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. <i>Psychiatr Serv</i>. 1998;49(9):1163-1172. doi:10.1176/ps.49.9.1163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9735957/pubmed" id="9735957" target="_blank">9735957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16055784">
<a name="16055784"></a>Penaskovic KM, Annamraju S, Kraus JE. Clozapine-induced allergic vasculitis. <i>Am J Psychiatry</i>. 2005;162(8):1543. doi:10.1176/appi.ajp.162.8.1543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16055784/pubmed" id="16055784" target="_blank">16055784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9328511">
<a name="9328511"></a>Pierides M. Clozapine monotherapy and ketoacidosis. <i>Br J Psychiatry</i>. 1997;171:90-91. doi:10.1192/bjp.171.1.90c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9328511/pubmed" id="9328511" target="_blank">9328511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22388466">
<a name="22388466"></a>Pintor L, Valldeoriola F, Baillés E, Martí MJ, Muñiz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. <i>Clin Neuropharmacol</i>. 2012;35(2):61-66. doi:10.1097/WNF.0b013e31824d5115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22388466/pubmed" id="22388466" target="_blank">22388466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11888352">
<a name="11888352"></a>Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. <i>Drug Saf</i>. 2002;25(2):91-110. doi:10.2165/00002018-200225020-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11888352/pubmed" id="11888352" target="_blank">11888352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15090561">
<a name="15090561"></a>Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up<i>. J Neurol Neurosurg Psychiatry</i>. 2004;75(5):689-695. doi:10.1136/jnnp.2003.029868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15090561/pubmed" id="15090561" target="_blank">15090561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.1">
<a name="Post.1"></a>Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 29. 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31528276">
<a name="31528276"></a>Poudyal R, Lohani S. Clozapine associated pulmonary embolism: systematic review. <i>J Community Hosp Intern Med Perspect</i>. 2019;9(4):300-304. doi:10.1080/20009666.2019.1627848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31528276/pubmed" id="31528276" target="_blank">31528276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16514524">
<a name="16514524"></a>Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. <i>Psychopharmacology (Berl)</i>. 2006;185(3):265-273.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16514524/pubmed" id="16514524" target="_blank">16514524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20661023">
<a name="20661023"></a>Praharaj SK, Jana AK, Goswami K, Das PR, Goyal N, Sinha VK. Salivary flow rate in patients with schizophrenia on clozapine. <i>Clin Neuropharmacol</i>. 2010;33(4):176-178. doi:10.1097/WNF.0b013e3181e204e0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20661023/pubmed" id="20661023" target="_blank">20661023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19833162">
<a name="19833162"></a>Praharaj SK, Venkatesh BG, Sarkhel S, Zia-ul-Haq M, Sinha VK. Clozapine-induced myoclonus: a case study and brief review. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2010;34(1):242-243. doi:10.1016/j.pnpbp.2009.10.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19833162/pubmed" id="19833162" target="_blank">19833162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25166892">
<a name="25166892"></a>Pridan S, Swartz M, Baruch Y, Tadger S, Plopski I, Barak Y. Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. <i>International Psychogeriatrics</i>. 2015;27(1):131-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25166892/pubmed" id="25166892" target="_blank">25166892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16143678">
<a name="16143678"></a>Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. <i>Postgrad Med J</i>. 2005;81(959):545-546. doi:10.1136/pgmj.2004.031161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16143678/pubmed" id="16143678" target="_blank">16143678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20631560">
<a name="20631560"></a>Rajji TK, Uchida H, Ismail Z, et al. Clozapine and global cognition in schizophrenia. <i>J Clin Psychopharmacol</i>. 2010;30(4):431-436. doi:10.1097/JCP.0b013e3181e69060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20631560/pubmed" id="20631560" target="_blank">20631560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26613638">
<a name="26613638"></a>Ramos Perdigués S, Sauras Quecuti R, Mané A, Mann L, Mundell C, Fernandez-Egea E. An observational study of clozapine induced sedation and its pharmacological management. <i>Eur Neuropsychopharmacol</i>. 2016;26(1):156-161. doi:10.1016/j.euroneuro.2015.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26613638/pubmed" id="26613638" target="_blank">26613638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32332465">
<a name="32332465"></a>Rask SM, Luoto KE, Solismaa A, Jokinen E, Jussila A, Kampman O. Clozapine-related diarrhea and colitis: report of 4 cases. <i>J Clin Psychopharmacol</i>. 2020;40(3):293-296. doi:10.1097/JCP.0000000000001204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32332465/pubmed" id="32332465" target="_blank">32332465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703015">
<a name="28703015"></a>Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. <i>Can J Psychiatry</i>. 2017;62(9):604-616. doi:10.1177/0706743717720448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28703015/pubmed" id="28703015" target="_blank">28703015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23179967">
<a name="23179967"></a>Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? <i>Psychopharmacology (Berl)</i>. 2013;225(3):505-518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23179967/pubmed" id="23179967" target="_blank">23179967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15949658">
<a name="15949658"></a>Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? <i>Schizophr Res</i>. 2005;76(2-3):267-272. doi: 10.1016/j.schres.2005.01.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15949658/pubmed" id="15949658" target="_blank">15949658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. <i>Am J Psychiatry</i>. 2016;173(5):543-546. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2015.173501. Accessed May 26, 2016. doi:10.1176/appi.ajp.2015.173501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26218604">
<a name="26218604"></a>Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. <i>Pharmacol Res</i>. 2015;101:74-85. doi:10.1016/j.phrs.2015.07.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/26218604/pubmed" id="26218604" target="_blank">26218604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010488">
<a name="23010488"></a>Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. <i>Schizophr Res</i>. 2012;141(2-3):173-178. doi:10.1016/j.schres.2012.08.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23010488/pubmed" id="23010488" target="_blank">23010488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20361910">
<a name="20361910"></a>Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. <i>J Clin Psychiatry</i>. 2010;71(8):976-981. doi:10.4088/JCP.09m05024yel<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20361910/pubmed" id="20361910" target="_blank">20361910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8830069">
<a name="8830069"></a>Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. <i>J Clin Psychopharmacol</i>. 1995;15(5):365-371. doi:10.1097/00004714-199510000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8830069/pubmed" id="8830069" target="_blank">8830069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23773887">
<a name="23773887"></a>Saenger RC, Finch TH, Francois D. Aspiration pneumonia due to clozapine-induced sialorrhea. <i>Clin Schizophr Relat Psychoses</i>. 2016;9(4):170-172. doi:10.3371/CSRP.SAFI.061213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23773887/pubmed" id="23773887" target="_blank">23773887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34749222">
<a name="34749222"></a>Sahyouni C, Hefazi E. Clozapine induced pericarditis: a case report. <i>Psychiatry Res</i>. 2021;305:114250. doi:10.1016/j.psychres.2021.114250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/34749222/pubmed" id="34749222" target="_blank">34749222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29554696">
<a name="29554696"></a>Sanader B, Grohmann R, Grötsch P, et al. Clozapine-induced DRESS syndrome: a case series from the AMSP multicenter drug safety surveillance project. <i>Pharmacopsychiatry</i>. 2019;52(3):156-159. doi:10.1055/a-0586-8983<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29554696/pubmed" id="29554696" target="_blank">29554696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29985823">
<a name="29985823"></a>Sarvaiya N, Lapitskaya Y, Dima L, Manu P. Clozapine-associated pulmonary embolism: a high-mortality, dose-independent and early-onset adverse effect. <i>Am J Ther</i>. 2018;25(4):e434-e438. doi:10.1097/MJT.0000000000000806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29985823/pubmed" id="29985823" target="_blank">29985823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24119631">
<a name="24119631"></a>Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. <i>Eur Psychiatry</i>. 2014;29(1):1-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24119631/pubmed" id="24119631" target="_blank">24119631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19213967">
<a name="19213967"></a>Seitz DP, Gill SS. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. <i>Psychosomatics</i>. 2009;50(1):8-15. doi:10.1176/appi.psy.50.1.8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19213967/pubmed" id="19213967" target="_blank">19213967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-65644">
<a name="65644"></a>Senn HJ, Jungi WF, Kunz H, Pöldinger W. Clozapine and agranulocytosis. <i>Lancet</i>. 1977;1(8010):547. doi:10.1016/s0140-6736(77)91410-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/65644/pubmed" id="65644" target="_blank">65644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23051123">
<a name="23051123"></a>Sharma TR, Chahil R. Dose dependent, new onset QTc prolongation in a patient with paranoid schizophrenia receiving Clozapine. <i>Asian J Psychiatr</i>. 2011;4(3):221-222. doi:10.1016/j.ajp.2011.06.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23051123/pubmed" id="23051123" target="_blank">23051123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16818861">
<a name="16818861"></a>Shaw P, Sporn A, Gogtay N, et al, "Childhood-Onset Schizophrenia: A Double-Blind, Randomized, Clozapine-Olanzapine Comparison," <i>Arch Gen Psych</i>, 2006, 63(7):721-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16818861/pubmed" id="16818861" target="_blank">16818861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20540690">
<a name="20540690"></a>Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM. Atypical antipsychotic metabolism and excretion. <i>Curr Drug Metab</i>. 2010;11(6):516-525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20540690/pubmed" id="20540690" target="_blank">20540690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22523509">
<a name="22523509"></a>Shin HW, Chung SJ. Drug-induced parkinsonism. <i>J Clin Neurol</i>. 2012;8(1):15-21. doi:10.3988/jcn.2012.8.1.15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22523509/pubmed" id="22523509" target="_blank">22523509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21645873">
<a name="21645873"></a>Shirani A, Paradiso S, Dyken ME. The impact of atypical antipsychotic use on obstructive sleep apnea: a pilot study and literature review. <i>Sleep Med</i>. 2011;12(6):591-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/21645873/pubmed" id="21645873" target="_blank">21645873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24419309">
<a name="24419309"></a>Shuman MD, Trigoboff E, Demler TL, Opler LA. Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients. <i>J Psychiatr Pract</i>. 2014;20(1):50-58. doi:10.1097/01.pra.0000442937.61575.26<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24419309/pubmed" id="24419309" target="_blank">24419309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32242646">
<a name="32242646"></a>Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapine during the COVID-19 pandemic [published online April 3, 2020]. <i>J Psychiatry Neurosci.</i> 2020;45(4):200061. doi:10.1503/jpn.200061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32242646/pubmed" id="32242646" target="_blank">32242646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31957459">
<a name="31957459"></a>Siskind D, Sidhu A, Cross J, et al. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. <i>Aust N Z J Psychiatry</i>. 2020;54(5):467-481. doi:10.1177/0004867419898760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31957459/pubmed" id="31957459" target="_blank">31957459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17390261">
<a name="17390261"></a>Soares-Weiser K, Fernandez HH. Tardive dyskinesia. <i>Semin Neurol</i>. 2007;27(2):159-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17390261/pubmed" id="17390261" target="_blank">17390261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28721057">
<a name="28721057"></a>Solmi M, Murru A, Pacchiarotti, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. <i>Ther Clin Risk Manag</i>. 2017;13:757-777. doi: 10.2147/TCRM.S117321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28721057/pubmed" id="28721057" target="_blank">28721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29439776">
<a name="29439776"></a>Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. <i>J Neurol Sci</i>. 2018;389:21-27. doi:10.1016/j.jns.2018.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29439776/pubmed" id="29439776" target="_blank">29439776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17885577">
<a name="17885577"></a>Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(10):1349-1356. doi:10.1097/chi.0b013e31812eed10<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17885577/pubmed" id="17885577" target="_blank">17885577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9804284">
<a name="9804284"></a>Squires RF, Saederup E. Clozapine and several other antipsychotic/antidepressant drugs preferentially block the same 'core' fraction of GABA(A) receptors. <i>Neurochem Res</i>. 1998;23(10):1283-1290. doi:10.1023/a:1020796200769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9804284/pubmed" id="9804284" target="_blank">9804284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20473075">
<a name="20473075"></a>Srinivasaraju R, Reddy YC, Pal PK, Math SB. Clozapine-associated cerebral venous thrombosis. <i>J Clin Psychopharmacol</i>. 2010;30(3):335-336. doi:10.1097/JCP.0b013e3181deb88a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/20473075/pubmed" id="20473075" target="_blank">20473075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34166590">
<a name="34166590"></a>Steinert T, Jans F. Six cases of perforated appendicitis during clozapine treatment. <i>J Clin Psychiatry</i>. 2021;82(4):20cr13841. doi:10.4088/JCP.20cr13841<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/34166590/pubmed" id="34166590" target="_blank">34166590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297. doi:10.1345/aph.1L066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11772153">
<a name="11772153"></a>Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. <i>Paediatr Drugs</i>. 2001;3(12):927-942. doi:10.2165/00128072-200103120-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11772153/pubmed" id="11772153" target="_blank">11772153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16096514">
<a name="16096514"></a>Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. <i>Int Clin Psychopharmacol</i>. 2005;20(5):243-251. doi:10.1097/01.yic.0000166405.49473.70<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/16096514/pubmed" id="16096514" target="_blank">16096514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stroup.1">
<a name="Stroup.1"></a>Stroup TS, Marder S. Schizophrenia in adults: maintenance therapy and side effect management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.1">
<a name="Stovall.1"></a>Stovall J. Bipolar mania and hypomania in adults: choosing pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31922262">
<a name="31922262"></a>Suvarna P, Kayarkatte MN, Shenoi SD, Jaiprakash P. A rare case of clozapine-induced symmetrical drug-related intertriginous and flexural exanthema with vasculitis-like lesions. <i>Contact Dermatitis</i>. 2020;82(5):318-320. doi:10.1111/cod.13468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31922262/pubmed" id="31922262" target="_blank">31922262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23744413">
<a name="23744413"></a>Szota A, Ogłodek E, Araszkiewicz A. Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine. <i>Pharmacol Rep</i>. 2013;65(2):279-287. doi:10.1016/s1734-1140(13)71004-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23744413/pubmed" id="23744413" target="_blank">23744413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30398998">
<a name="30398998"></a>Szota AM, Araszkiewicz AS. The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors. <i>Int Clin Psychopharmacol</i>. 2019;34(1):1-8. doi:10.1097/YIC.0000000000000244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/30398998/pubmed" id="30398998" target="_blank">30398998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31922669">
<a name="31922669"></a>Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). <i>World Psychiatry</i>. 2020;19(1):61-68. doi:10.1002/wps.20699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31922669/pubmed" id="31922669" target="_blank">31922669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28044008">
<a name="28044008"></a>Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. <i>Schizophr Bull</i>. 2017;43(4):862-871. doi:10.1093/schbul/sbw171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28044008/pubmed" id="28044008" target="_blank">28044008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27182769">
<a name="27182769"></a>Takeuchi H, Powell V, Geisler S, et al. Clozapine administration in clinical practice: once-daily versus divided dosing. <i>Acta Psychiatr Scand</i>. 2016;134(3):234-240. doi:10.1111/acps.12593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/27182769/pubmed" id="27182769" target="_blank">27182769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33410989">
<a name="33410989"></a>Tan MSA, Honarparvar F, Falconer JR, Parekh HS, Pandey P, Siskind DJ. A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. <i>Psychopharmacology (Berl)</i>. 2021;238(3):615-637. doi:10.1007/s00213-020-05746-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/33410989/pubmed" id="33410989" target="_blank">33410989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12897222">
<a name="12897222"></a>Tanner MA, Culling W. Clozapine associated dilated cardiomyopathy. <i>Postgrad Med J</i>. 2003;79(933):412-413. doi:10.1136/pmj.79.933.412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/12897222/pubmed" id="12897222" target="_blank">12897222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24911442">
<a name="24911442"></a>Tatar ZB, Oflaz S, Baran B. A case of late-onset angioedema associated with clozapine and redevelopment of angioedema with olanzapine. <i>J Clin Psychopharmacol</i>. 2014;34(4):523-525. doi:10.1097/JCP.0000000000000153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24911442/pubmed" id="24911442" target="_blank">24911442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29401113">
<a name="29401113"></a>Teodorescu A, Dima L, Ifteni P, Rogozea LM. Clozapine for treatment-refractory behavioral disturbance in dementia. <i>Am J Ther</i>. 2018;25(3):e320-e325. doi:10.1097/MJT.0000000000000735<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29401113/pubmed" id="29401113" target="_blank">29401113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36066404">
<a name="36066404"></a>Teodoro T, Nogueira V, Aldeias J, Teles Martins M, Salgado J. Clozapine associated periorbital edema in first episode psychosis: a case report of a rare adverse effect in treatment-resistant schizophrenia. <i>J Clin Psychopharmacol</i>. 2022;42(6):594-596. doi:10.1097/JCP.0000000000001600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/36066404/pubmed" id="36066404" target="_blank">36066404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30618473">
<a name="30618473"></a>Thomson SR, Patil N, Ommurugan B, Bhandary RK. A case of hyper sexuality probably associated with clozapine. <i>Psychopharmacol Bull</i>. 2018;48(4):20-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/30618473/pubmed" id="30618473" target="_blank">30618473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19595447">
<a name="19595447"></a>Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). <i>Lancet</i>. 2009;374(9690):620-627. doi:10.1016/S0140-6736(09)60742-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19595447/pubmed" id="19595447" target="_blank">19595447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(6):e57]. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24803473">
<a name="24803473"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appears in <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(6):981]. <i>Circ Cardiovasc Qual Outcomes</i>. 2014;7(3):381-390. doi:10.1161/CIRCOUTCOMES.113.000651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24803473/pubmed" id="24803473" target="_blank">24803473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11249804">
<a name="11249804"></a>Tohen M, Jacobs TG, Feldman PD. Onset of action of antipsychotics in the treatment of mania. <i>Bipolar Disord</i>. 2000;2(3 pt 2):261-268. doi:10.1034/j.1399-5618.2000.20307.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/11249804/pubmed" id="11249804" target="_blank">11249804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33173520">
<a name="33173520"></a>Torrico T, Crandall RO, Meza C, Abdijadid S. Clozapine-induced pneumonitis: a case report. <i>Front Psychiatry</i>. 2020;11:572102. doi:10.3389/fpsyt.2020.572102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/33173520/pubmed" id="33173520" target="_blank">33173520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353146">
<a name="21353146"></a>Tripp AC. Nonfatal pulmonary embolus associated with clozapine treatment: a case series. <i>Gen Hosp Psychiatry</i>. 2011;33(1). doi:10.1016/j.genhosppsych.2010.11.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/21353146/pubmed" id="21353146" target="_blank">21353146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22626633">
<a name="22626633"></a>Trollor JN, Chen X, Chitty K, Sachdev PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. <i>Br J Psychiatry</i>. 2012;201(1):52-56. doi:10.1192/bjp.bp.111.105189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22626633/pubmed" id="22626633" target="_blank">22626633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24595134">
<a name="24595134"></a>Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. <i>BMJ Open</i>. 2014;4(3):e004216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/24595134/pubmed" id="24595134" target="_blank">24595134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9330014">
<a name="9330014"></a>Turetz M, Mozes T, Toren P, et al. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. <i>Br J Psychiatry</i>. 1997;170:507-510. doi:10.1192/bjp.170.6.507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/9330014/pubmed" id="9330014" target="_blank">9330014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31738190">
<a name="31738190"></a>Uzun Ö, Bolu A, Taşçi AB, Oğur B. Knee buckling (negative myoclonus) associated with clozapine: reports on 3 cases. <i>Clin Neuropharmacol</i>. 2020;43(1):26-27. doi:10.1097/WNF.0000000000000370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31738190/pubmed" id="31738190" target="_blank">31738190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31342625">
<a name="31342625"></a>Valladales-Restrepo LF, Duran-Lengua M, Machado-Alba JE. Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer's disease patients. <i>Geriatr Gerontol Int</i>. 2019;19(9):913-917. doi:10.1111/ggi.13748<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31342625/pubmed" id="31342625" target="_blank">31342625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10473482">
<a name="10473482"></a>van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. <i>BMJ</i>. 1999;319(7210):623-626. doi:10.1136/bmj.319.7210.623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/10473482/pubmed" id="10473482" target="_blank">10473482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17401555">
<a name="17401555"></a>van Marum RJ, Wegewijs MA, Loonen AJ, Beers E. Hypothermia following antipsychotic drug use. <i>Eur J Clin Pharmacol</i>. 2007;63(6):627-631. doi:10.1007/s00228-007-0294-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17401555/pubmed" id="17401555" target="_blank">17401555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18348593">
<a name="18348593"></a>van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. <i>J Clin Psychiatry</i>. 2008;69(3):472-479. doi:10.4088/jcp.v69n0320<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/18348593/pubmed" id="18348593" target="_blank">18348593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8942454">
<a name="8942454"></a>VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. <i>Am J Psychiatry</i>. 1996;153(12):1579-1584. doi:10.1176/ajp.153.12.1579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/8942454/pubmed" id="8942454" target="_blank">8942454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23983927">
<a name="23983927"></a>Varma S, Bishara D, Besag FM, Taylor D. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. <i>Ther Adv Psychopharmacol</i>. 2011;1(2):47-66. doi:10.1177/2045125311405566<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23983927/pubmed" id="23983927" target="_blank">23983927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27681143">
<a name="27681143"></a>Vasudev K, Choi YH, Norman R, Kim RB, Schwarz UI. Genetic determinants of clozapine-induced metabolic side effects. <i>Can J Psychiatry</i>. 2017;62(2):138-149. doi:10.1177/0706743716670128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/27681143/pubmed" id="27681143" target="_blank">27681143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19127092">
<a name="19127092"></a>Vayá A, Lopez M, Plumé G, Ribes J. Upper-extremity deep vein thrombosis in a patient on clozapine therapy carrying the prothrombin G20210A mutation. <i>Pathophysiol Haemost Thromb</i>. 2008;36(2):105-107. doi:10.1159/000173731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/19127092/pubmed" id="19127092" target="_blank">19127092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29697804">
<a name="29697804"></a>Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutterland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. <i>Schizophr Bull</i>. 2019;45(2):315-329. doi:10.1093/schbul/sby052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29697804/pubmed" id="29697804" target="_blank">29697804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TruPharma.1">
<a name="TruPharma.1"></a>Versacloz (clozapine) [prescribing information]. Tampa, FL: TruPharma LLC; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23858394">
<a name="23858394"></a>Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. <i>Tremor Other Hyperkinet Mov (N Y)</i>. 2013;3:tre-03-161-4138-1. doi:10.7916/D88P5Z71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/23858394/pubmed" id="23858394" target="_blank">23858394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834089">
<a name="31834089"></a>Wang Y, Gong Y, Liu Z, Fu Z, Xue Y, Huang G. Acute bilateral coronary artery thrombosis and myocardial infarction in a 25-year-old man after long-term oral clozapine treatment. <i>J Clin Psychopharmacol</i>. 2020;40(1):84-86. doi:10.1097/JCP.0000000000001156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/31834089/pubmed" id="31834089" target="_blank">31834089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25324614">
<a name="25324614"></a>Wang Y, He R, Zhang H. Case report on clozapine-associated neuroleptic malignant syndrome. <i>Shanghai Arch Psychiatry</i>. 2012;24(2):116-117. doi:10.3969/j.issn.1002-0829.2012.02.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25324614/pubmed" id="25324614" target="_blank">25324614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12503253">
<a name="12503253"></a>Warner B, Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. <i>Adverse Drug React Toxicol Rev</i>. 2002;21(4):189-203. doi:10.1007/BF03256196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/12503253/pubmed" id="12503253" target="_blank">12503253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15258717">
<a name="15258717"></a>Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. <i>Psychopharmacology (Berl)</i>. 2004;177(1-2):207-216. doi:10.1007/s00213-004-1940-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15258717/pubmed" id="15258717" target="_blank">15258717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27780320">
<a name="27780320"></a>Welten CC, Koeter MW, Wohlfarth TD, et al. Early nonresponse in the antipsychotic treatment of acute mania: a criterion for reconsidering treatment? Results from an individual patient data meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(9):e1117-e1123. doi:10.4088/JCP.15r10051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/27780320/pubmed" id="27780320" target="_blank">27780320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114630">
<a name="22114630"></a>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. <i>Dtsch Arztebl Int</i>. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/22114630/pubmed" id="22114630" target="_blank">22114630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15206664">
<a name="15206664"></a>Wheatley M, Plant J, Reader H, et al, "Clozapine Treatment of Adolescents With Posttraumatic Stress Disorder and Psychotic Symptoms," <i>J Clin Psychopharmacol</i>, 2004, 24(2):167-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/15206664/pubmed" id="15206664" target="_blank">15206664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28984748">
<a name="28984748"></a>Wiciński M, Węclewicz MM. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. <i>Curr Opin Hematol</i>. 2018;25(1):22-28. doi:10.1097/MOH.0000000000000391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28984748/pubmed" id="28984748" target="_blank">28984748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25537107">
<a name="25537107"></a>Williams AM, Park SH. Seizure associated with clozapine: incidence, etiology, and management. <i>CNS Drugs</i>. 2015;29(2):101-111. doi:10.1007/s40263-014-0222-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25537107/pubmed" id="25537107" target="_blank">25537107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17688010">
<a name="17688010"></a>Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. <i>Can J Psychiatry</i>. 2007;52(7):457-463. doi:10.1177/070674370705200708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/17688010/pubmed" id="17688010" target="_blank">17688010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27249081">
<a name="27249081"></a>Wu CS, Wang SC, Yeh IJ, Liu SK. Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. <i>J Clin Psychiatry</i>. 2016;77(5):e573-e579. doi:10.4088/JCP.15m09898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/27249081/pubmed" id="27249081" target="_blank">27249081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25497507">
<a name="25497507"></a>Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: a case report and review of the literature. <i>Psychosomatics</i>. 2014;55(6):686-691. doi:10.1016/j.psym.2014.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25497507/pubmed" id="25497507" target="_blank">25497507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25914536">
<a name="25914536"></a>Wu MK, Chung W, Wu CK, Tseng PT. The severe complication of Stevens-Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: a case report. <i>Neuropsychiatr Dis Treat</i>. 2015;11:1039-1041. doi:10.2147/NDT.S79327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25914536/pubmed" id="25914536" target="_blank">25914536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25210451">
<a name="25210451"></a>Wu Chou AI, Lu ML, Shen WW. Hepatotoxicity induced by clozapine: a case report and review of literature. <i>Neuropsychiatr Dis Treat</i>. 2014;10:1585-1587. doi:10.2147/NDT.S67654<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/25210451/pubmed" id="25210451" target="_blank">25210451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi: 10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29670504">
<a name="29670504"></a>Yuen JWY, Kim DD, Procyshyn RM, White RF, Honer WG, Barr AM. Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review. <i>Front Neurosci</i>. 2018;12:203. doi:10.3389/fnins.2018.00203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/29670504/pubmed" id="29670504" target="_blank">29670504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28936184">
<a name="28936184"></a>Zonnenberg C, Bueno-de-Mesquita JM, Ramlal D, Blom JD. Hypothermia due to antipsychotic medication: a systematic review. <i>Front Psychiatry</i>. 2017;8:165. doi:10.3389/fpsyt.2017.00165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/clozapine-drug-information/abstract-text/28936184/pubmed" id="28936184" target="_blank">28936184</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9289 Version 603.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
